{ "version": "2.2", "instance": { "form20-f.htm": { "nsprefix": "OKYO", "nsuri": "http://okyopharma.com/20260331", "dts": { "inline": { "local": [ "form20-f.htm" ] }, "schema": { "local": [ "okyo-20260331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/rol_ifrs_ea-dim_2025-03-27.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/rol_full_ifrs-dim_2025-03-27.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd", "https://xbrl.sec.gov/country/2025/country-2025.xsd", "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd", "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd", "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" ] }, "calculationLink": { "local": [ "okyo-20260331_cal.xml" ] }, "definitionLink": { "local": [ "okyo-20260331_def.xml" ], "remote": [ "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/dim_ifrs_ea_2025-03-27_role-995000.xml", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/dim_full_ifrs_2025-03-27_role-995000.xml" ] }, "labelLink": { "local": [ "okyo-20260331_lab.xml" ] }, "presentationLink": { "local": [ "okyo-20260331_pre.xml" ] } }, "keyStandard": 206, "keyCustom": 112, "axisStandard": 14, "axisCustom": 2, "memberStandard": 9, "memberCustom": 52, "hidden": { "total": 214, "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full": 88, "http://okyopharma.com/20260331": 123, "http://xbrl.sec.gov/dei/2025": 3 }, "contextCount": 184, "entityCount": 1, "segmentCount": 61, "elementCount": 587, "unitCount": 5, "baseTaxonomies": { "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full": 624, "http://xbrl.sec.gov/dei/2025": 44, "http://xbrl.sec.gov/cyd/2025": 6, "http://xbrl.sec.gov/ecd/2025": 1 }, "report": { "R1": { "role": "http://okyopharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R2": { "role": "http://okyopharma.com/role/BalanceSheets", "longName": "00000002 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2026-03-31", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2026-03-31", "name": "ifrs-full:ShorttermInvestmentsClassifiedAsCashEquivalents", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "unique": true } }, "R3": { "role": "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss", "longName": "00000003 - Statement - Consolidated Statements of Operations and Comprehensive Loss", "shortName": "Consolidated Statements of Operations and Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:ResearchAndDevelopmentExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:ResearchAndDevelopmentExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R4": { "role": "http://okyopharma.com/role/StatementsOfShareholdersEquity", "longName": "00000004 - Statement - Consolidated Statements of Shareholders' Equity", "shortName": "Consolidated Statements of Shareholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "AsOf2023-03-31_ifrs-full_IssuedCapitalMember", "name": "ifrs-full:Equity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-03-31_ifrs-full_IssuedCapitalMember", "name": "ifrs-full:Equity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R5": { "role": "http://okyopharma.com/role/StatementsOfCashFlows", "longName": "00000005 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:ProfitLossBeforeTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:AdjustmentsForSharebasedPayments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "unique": true } }, "R6": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "longName": "995447 - Disclosure - Insider Trading Policies and Procedures", "shortName": "Insider Trading Policies and Procedures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "6", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R7": { "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure", "shortName": "Cybersecurity Risk Management and Strategy Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R8": { "role": "http://okyopharma.com/role/ReportingEntity", "longName": "999013 - Disclosure - Reporting Entity", "shortName": "Reporting Entity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "OKYO:DisclosureOfNatureOfBusinessExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "OKYO:DisclosureOfNatureOfBusinessExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R9": { "role": "http://okyopharma.com/role/AccountingPolicies", "longName": "999014 - Disclosure - ACCOUNTING POLICIES", "shortName": "ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R10": { "role": "http://okyopharma.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertainty", "longName": "999015 - Disclosure - CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY", "shortName": "CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "OKYO:DisclosureCriticalAccountingJudgementsAndKeySourcesOfEstimationUncertainty", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "OKYO:DisclosureCriticalAccountingJudgementsAndKeySourcesOfEstimationUncertainty", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R11": { "role": "http://okyopharma.com/role/OperatingExpenses", "longName": "999016 - Disclosure - OPERATING EXPENSES", "shortName": "OPERATING EXPENSES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R12": { "role": "http://okyopharma.com/role/SegmentalReporting", "longName": "999017 - Disclosure - SEGMENTAL REPORTING", "shortName": "SEGMENTAL REPORTING", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R13": { "role": "http://okyopharma.com/role/EmployeesIncludingOfficersExecutiveAndNon-executiveDirectors", "longName": "999018 - Disclosure - EMPLOYEES INCLUDING OFFICERS, EXECUTIVE AND NON-EXECUTIVE DIRECTORS", "shortName": "EMPLOYEES INCLUDING OFFICERS, EXECUTIVE AND NON-EXECUTIVE DIRECTORS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "OKYO:DisclosureOfEmployeeDetailsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "OKYO:DisclosureOfEmployeeDetailsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R14": { "role": "http://okyopharma.com/role/RemunerationOfKeyManagementPersonnel", "longName": "999019 - Disclosure - REMUNERATION OF KEY MANAGEMENT PERSONNEL", "shortName": "REMUNERATION OF KEY MANAGEMENT PERSONNEL", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R15": { "role": "http://okyopharma.com/role/Taxation", "longName": "999020 - Disclosure - TAXATION", "shortName": "TAXATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R16": { "role": "http://okyopharma.com/role/FinanceIncomeAndCosts", "longName": "999021 - Disclosure - FINANCE INCOME AND COSTS", "shortName": "FINANCE INCOME AND COSTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R17": { "role": "http://okyopharma.com/role/PropertyPlantAndEquipment", "longName": "999022 - Disclosure - PROPERTY, PLANT AND EQUIPMENT", "shortName": "PROPERTY, PLANT AND EQUIPMENT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R18": { "role": "http://okyopharma.com/role/PrepaidExpensesAndOtherReceivables", "longName": "999023 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES", "shortName": "PREPAID EXPENSES AND OTHER RECEIVABLES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "OKYO:DisclosureOfPrepaidExpensesAndOtherReceivablesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "OKYO:DisclosureOfPrepaidExpensesAndOtherReceivablesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R19": { "role": "http://okyopharma.com/role/TradeAndOtherPayables", "longName": "999024 - Disclosure - TRADE AND OTHER PAYABLES", "shortName": "TRADE AND OTHER PAYABLES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R20": { "role": "http://okyopharma.com/role/CapitalAndReserves", "longName": "999025 - Disclosure - CAPITAL AND RESERVES", "shortName": "CAPITAL AND RESERVES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R21": { "role": "http://okyopharma.com/role/ShareOptionsAndWarrants", "longName": "999026 - Disclosure - SHARE OPTIONS AND WARRANTS", "shortName": "SHARE OPTIONS AND WARRANTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R22": { "role": "http://okyopharma.com/role/FinancialInstruments", "longName": "999027 - Disclosure - FINANCIAL INSTRUMENTS", "shortName": "FINANCIAL INSTRUMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R23": { "role": "http://okyopharma.com/role/RelatedPartyTransactions", "longName": "999028 - Disclosure - RELATED PARTY TRANSACTIONS", "shortName": "RELATED PARTY TRANSACTIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R24": { "role": "http://okyopharma.com/role/BasicAndDilutedLossPerShare", "longName": "999029 - Disclosure - BASIC AND DILUTED LOSS PER SHARE", "shortName": "BASIC AND DILUTED LOSS PER SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R25": { "role": "http://okyopharma.com/role/Leases", "longName": "999030 - Disclosure - LEASES", "shortName": "LEASES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:DisclosureOfLeasesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:DisclosureOfLeasesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R26": { "role": "http://okyopharma.com/role/AuditorsRemuneration", "longName": "999031 - Disclosure - AUDITOR\u2019S REMUNERATION", "shortName": "AUDITOR\u2019S REMUNERATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:DisclosureOfAuditorsRemunerationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:DisclosureOfAuditorsRemunerationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R27": { "role": "http://okyopharma.com/role/CashAndCashEquivalentsAndShortTermInvestments", "longName": "999032 - Disclosure - CASH AND CASH EQUIVALENTS AND SHORT TERM INVESTMENTS", "shortName": "CASH AND CASH EQUIVALENTS AND SHORT TERM INVESTMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R28": { "role": "http://okyopharma.com/role/ConvertibleLoanInstruments", "longName": "999033 - Disclosure - CONVERTIBLE LOAN INSTRUMENTS", "shortName": "CONVERTIBLE LOAN INSTRUMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "OKYO:DisclosureOfConvertibleLoanInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "OKYO:DisclosureOfConvertibleLoanInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R29": { "role": "http://okyopharma.com/role/CommitmentsAndContingencies", "longName": "999034 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "29", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R30": { "role": "http://okyopharma.com/role/PostBalanceSheetEvents", "longName": "999035 - Disclosure - POST BALANCE SHEET EVENTS", "shortName": "POST BALANCE SHEET EVENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "30", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R31": { "role": "http://okyopharma.com/role/AccountingPoliciesPolicies", "longName": "999036 - Disclosure - ACCOUNTING POLICIES (Policies)", "shortName": "ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "31", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "OKYO:DisclosureOfAccountingPoliciesBasisOfPresentationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "OKYO:DisclosureOfAccountingPoliciesBasisOfPresentationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R32": { "role": "http://okyopharma.com/role/AccountingPoliciesTables", "longName": "999037 - Disclosure - ACCOUNTING POLICIES (Tables)", "shortName": "ACCOUNTING POLICIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "OKYO:DisclosureOfEstimatedUsefulLivesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "OKYO:DisclosureOfEstimatedUsefulLivesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R33": { "role": "http://okyopharma.com/role/OperatingExpensesTables", "longName": "999038 - Disclosure - OPERATING EXPENSES (Tables)", "shortName": "OPERATING EXPENSES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "OKYO:DisclosureOfDetailedInformationAboutOperatingExpensesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "OKYO:DisclosureOfDetailedInformationAboutOperatingExpensesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R34": { "role": "http://okyopharma.com/role/EmployeesIncludingOfficersExecutiveAndNon-executiveDirectorsTables", "longName": "999039 - Disclosure - EMPLOYEES INCLUDING OFFICERS, EXECUTIVE AND NON-EXECUTIVE DIRECTORS (Tables)", "shortName": "EMPLOYEES INCLUDING OFFICERS, EXECUTIVE AND NON-EXECUTIVE DIRECTORS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "OKYO:DisclosureOfDetailedInformationAboutEmployeesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "OKYO:DisclosureOfEmployeeDetailsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "OKYO:DisclosureOfDetailedInformationAboutEmployeesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "OKYO:DisclosureOfEmployeeDetailsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R35": { "role": "http://okyopharma.com/role/RemunerationOfKeyManagementPersonnelTables", "longName": "999040 - Disclosure - REMUNERATION OF KEY MANAGEMENT PERSONNEL (Tables)", "shortName": "REMUNERATION OF KEY MANAGEMENT PERSONNEL (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R36": { "role": "http://okyopharma.com/role/TaxationTables", "longName": "999041 - Disclosure - TAXATION (Tables)", "shortName": "TAXATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:DisclosureOfTaxReceivablesAndPayablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfIncomeTaxExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:DisclosureOfTaxReceivablesAndPayablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfIncomeTaxExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R37": { "role": "http://okyopharma.com/role/FinanceIncomeAndCostsTables", "longName": "999042 - Disclosure - FINANCE INCOME AND COSTS (Tables)", "shortName": "FINANCE INCOME AND COSTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:DisclosureOfFinanceCostExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:DisclosureOfFinanceCostExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R38": { "role": "http://okyopharma.com/role/PropertyPlantAndEquipmentTables", "longName": "999043 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)", "shortName": "PROPERTY, PLANT AND EQUIPMENT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R39": { "role": "http://okyopharma.com/role/PrepaidExpensesAndOtherReceivablesTables", "longName": "999044 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)", "shortName": "PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "OKYO:DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivablesExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "OKYO:DisclosureOfPrepaidExpensesAndOtherReceivablesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "OKYO:DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivablesExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "OKYO:DisclosureOfPrepaidExpensesAndOtherReceivablesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R40": { "role": "http://okyopharma.com/role/TradeAndOtherPayablesTables", "longName": "999045 - Disclosure - TRADE AND OTHER PAYABLES (Tables)", "shortName": "TRADE AND OTHER PAYABLES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "OKYO:DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "OKYO:DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R41": { "role": "http://okyopharma.com/role/CapitalAndReservesTables", "longName": "999046 - Disclosure - CAPITAL AND RESERVES (Tables)", "shortName": "CAPITAL AND RESERVES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R42": { "role": "http://okyopharma.com/role/ShareOptionsAndWarrantsTables", "longName": "999047 - Disclosure - SHARE OPTIONS AND WARRANTS (Tables)", "shortName": "SHARE OPTIONS AND WARRANTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "OKYO:DisclosureOfDetailedInformationAboutOptionsOutstandingAndWeightedAverageExercisePriceExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "OKYO:DisclosureOfDetailedInformationAboutOptionsOutstandingAndWeightedAverageExercisePriceExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R43": { "role": "http://okyopharma.com/role/FinancialInstrumentsTables", "longName": "999048 - Disclosure - FINANCIAL INSTRUMENTS (Tables)", "shortName": "FINANCIAL INSTRUMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "OKYO:DisclosureOfDetailedInformationOfMaturitiesOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "OKYO:DisclosureOfDetailedInformationOfMaturitiesOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R44": { "role": "http://okyopharma.com/role/BasicAndDilutedLossPerShareTables", "longName": "999049 - Disclosure - BASIC AND DILUTED LOSS PER SHARE (Tables)", "shortName": "BASIC AND DILUTED LOSS PER SHARE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "44", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:EarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:EarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R45": { "role": "http://okyopharma.com/role/LeasesTables", "longName": "999050 - Disclosure - LEASES (Tables)", "shortName": "LEASES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "45", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "OKYO:DisclosureOfDetailedInformationAboutContractualMaturitiesOfLeaseLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfLeasesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "OKYO:DisclosureOfDetailedInformationAboutContractualMaturitiesOfLeaseLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfLeasesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R46": { "role": "http://okyopharma.com/role/AuditorsRemunerationTables", "longName": "999051 - Disclosure - AUDITOR\u2019S REMUNERATION (Tables)", "shortName": "AUDITOR\u2019S REMUNERATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "46", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "OKYO:DisclosureOfDetailedInformationAboutCompanyAuditorsFeesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfAuditorsRemunerationExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "OKYO:DisclosureOfDetailedInformationAboutCompanyAuditorsFeesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfAuditorsRemunerationExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R47": { "role": "http://okyopharma.com/role/CashAndCashEquivalentsAndShortTermInvestmentsTables", "longName": "999052 - Disclosure - CASH AND CASH EQUIVALENTS AND SHORT TERM INVESTMENTS (Tables)", "shortName": "CASH AND CASH EQUIVALENTS AND SHORT TERM INVESTMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "47", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "OKYO:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "OKYO:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R48": { "role": "http://okyopharma.com/role/CommitmentsAndContingenciesTables", "longName": "999053 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)", "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "48", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "OKYO:DisclosureOfDetailedInformationAboutMilestonesPaymentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "OKYO:DisclosureOfDetailedInformationAboutMilestonesPaymentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R49": { "role": "http://okyopharma.com/role/AccountingPoliciesDetailsNarrative", "longName": "999054 - Disclosure - ACCOUNTING POLICIES (Details Narrative)", "shortName": "ACCOUNTING POLICIES (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "AsOf2026-03-31", "name": "ifrs-full:RetainedEarnings", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2018-12-31", "name": "ifrs-full:RetainedEarnings", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "span", "span", "p", "ifrs-full:DisclosureOfGoingConcernExplanatory", "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "unique": true } }, "R50": { "role": "http://okyopharma.com/role/DisclosureOfEstimatedUsefulLivesDetails", "longName": "999055 - Disclosure - DISCLOSURE OF ESTIMATED USEFUL LIVES (Details)", "shortName": "DISCLOSURE OF ESTIMATED USEFUL LIVES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "From2025-04-012026-03-31_ifrs-full_ComputerEquipmentMember", "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "td", "tr", "table", "OKYO:DisclosureOfEstimatedUsefulLivesExplanatory", "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-012026-03-31_ifrs-full_ComputerEquipmentMember", "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "td", "tr", "table", "OKYO:DisclosureOfEstimatedUsefulLivesExplanatory", "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R51": { "role": "http://okyopharma.com/role/ScheduleOfOperatingExpensesDetails", "longName": "999056 - Disclosure - SCHEDULE OF OPERATING EXPENSES (Details)", "shortName": "SCHEDULE OF OPERATING EXPENSES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "OKYO:KeyManagementPersonnelCompensationDirectorFees", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "OKYO:DisclosureOfDetailedInformationAboutOperatingExpensesExplanatory", "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "OKYO:KeyManagementPersonnelCompensationDirectorFees", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "OKYO:DisclosureOfDetailedInformationAboutOperatingExpensesExplanatory", "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R52": { "role": "http://okyopharma.com/role/ScheduleOfEmployeesCostAndNumberOfEmployeesExplanatoryDetails", "longName": "999057 - Disclosure - SCHEDULE OF EMPLOYEES COST AND NUMBER OF EMPLOYEES EXPLANATORY (Details)", "shortName": "SCHEDULE OF EMPLOYEES COST AND NUMBER OF EMPLOYEES EXPLANATORY (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "OKYO:DirectorsSalaries", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "OKYO:DisclosureOfDetailedInformationAboutEmployeesExplanatory", "OKYO:DisclosureOfEmployeeDetailsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "OKYO:DirectorsSalaries", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "OKYO:DisclosureOfDetailedInformationAboutEmployeesExplanatory", "OKYO:DisclosureOfEmployeeDetailsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R53": { "role": "http://okyopharma.com/role/ScheduleOfKeyManagementPersonnelCompensationDetails", "longName": "999058 - Disclosure - SCHEDULE OF KEY MANAGEMENT PERSONNEL COMPENSATION (Details)", "shortName": "SCHEDULE OF KEY MANAGEMENT PERSONNEL COMPENSATION (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "From2025-04-012026-03-31_custom_FeeAndShortTermEmployeeBenefitsMember", "name": "ifrs-full:KeyManagementPersonnelCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-012026-03-31_custom_FeeAndShortTermEmployeeBenefitsMember", "name": "ifrs-full:KeyManagementPersonnelCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R54": { "role": "http://okyopharma.com/role/RemunerationOfKeyManagementPersonnelDetailsNarrative", "longName": "999059 - Disclosure - REMUNERATION OF KEY MANAGEMENT PERSONNEL (Details Narrative)", "shortName": "REMUNERATION OF KEY MANAGEMENT PERSONNEL (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "From2024-04-012025-03-31", "name": "OKYO:PostemploymentSeverancePayments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-012025-03-31", "name": "OKYO:PostemploymentSeverancePayments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R55": { "role": "http://okyopharma.com/role/ScheduleOfShareOptionsGrantedToDirectorsDetails", "longName": "999060 - Disclosure - SCHEDULE OF SHARE OPTIONS GRANTED TO DIRECTORS (Details)", "shortName": "SCHEDULE OF SHARE OPTIONS GRANTED TO DIRECTORS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "OKYO:DisclosureOfDetailedInformationAboutOptionsOutstandingAndWeightedAverageExercisePriceExplanatory", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2025-04-012026-03-31_custom_DirectorsMember", "name": "ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "OKYO:DisclosureOfDetailedInformationShareOptionsGrantedToDirectorsExplanatory", "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "unique": true } }, "R56": { "role": "http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetails", "longName": "999061 - Disclosure - SCHEDULE OF TAX CREDIT PERIOD (Details)", "shortName": "SCHEDULE OF TAX CREDIT PERIOD (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:CurrentTaxExpenseIncome", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfTaxReceivablesAndPayablesExplanatory", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:CurrentTaxExpenseIncome", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfTaxReceivablesAndPayablesExplanatory", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R57": { "role": "http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetailsParanthetical", "longName": "999062 - Disclosure - SCHEDULE OF TAX CREDIT PERIOD (Details) (Paranthetical)", "shortName": "SCHEDULE OF TAX CREDIT PERIOD (Details) (Paranthetical)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:ApplicableTaxRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "span", "td", "tr", "table", "ifrs-full:DisclosureOfTaxReceivablesAndPayablesExplanatory", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:ApplicableTaxRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "span", "td", "tr", "table", "ifrs-full:DisclosureOfTaxReceivablesAndPayablesExplanatory", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R58": { "role": "http://okyopharma.com/role/TaxationDetailsNarrative", "longName": "999063 - Disclosure - TAXATION (Details Narrative)", "shortName": "TAXATION (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:TaxEffectOfTaxLosses", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:TaxEffectOfTaxLosses", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R59": { "role": "http://okyopharma.com/role/ScheduleOfFinanceIncomeAndCostsDetails", "longName": "999064 - Disclosure - SCHEDULE OF FINANCE INCOME AND COSTS (Details)", "shortName": "SCHEDULE OF FINANCE INCOME AND COSTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:RevenueFromInterest", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfFinanceCostExplanatory", "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:RevenueFromInterest", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfFinanceCostExplanatory", "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R60": { "role": "http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentDetails", "longName": "999065 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details)", "shortName": "SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "AsOf2025-03-31", "name": "OKYO:PropertyPlantAndEquipmentCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-31", "name": "OKYO:PropertyPlantAndEquipmentCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "unique": true } }, "R61": { "role": "http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentLocatedInOperatingSegmentDetails", "longName": "999066 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT LOCATED IN OPERATING SEGMENT (Details)", "shortName": "SCHEDULE OF PROPERTY PLANT AND EQUIPMENT LOCATED IN OPERATING SEGMENT (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "AsOf2026-03-31", "name": "ifrs-full:PropertyPlantAndEquipment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2025-03-31_custom_UKMember", "name": "ifrs-full:PropertyPlantAndEquipment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "OKYO:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentLocatedOperatingSegmentExplanatory", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "unique": true } }, "R62": { "role": "http://okyopharma.com/role/ScheduleOfPrepaidExpensesAndOtherReceivablesDetails", "longName": "999067 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER RECEIVABLES (Details)", "shortName": "SCHEDULE OF PREPAID EXPENSES AND OTHER RECEIVABLES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "AsOf2026-03-31", "name": "ifrs-full:OtherReceivables", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "OKYO:DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivablesExplanatoryTextBlock", "OKYO:DisclosureOfPrepaidExpensesAndOtherReceivablesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2026-03-31", "name": "ifrs-full:OtherReceivables", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "OKYO:DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivablesExplanatoryTextBlock", "OKYO:DisclosureOfPrepaidExpensesAndOtherReceivablesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R63": { "role": "http://okyopharma.com/role/ScheduleOfTradeAndOtherPayablesDetails", "longName": "999068 - Disclosure - SCHEDULE OF TRADE AND OTHER PAYABLES (Details)", "shortName": "SCHEDULE OF TRADE AND OTHER PAYABLES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "AsOf2026-03-31", "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "OKYO:DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatory", "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2026-03-31", "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "OKYO:DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatory", "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R64": { "role": "http://okyopharma.com/role/ScheduleOfAuthorizedIssueUnlimitedNumberOfParValueSharesDetails", "longName": "999069 - Disclosure - SCHEDULE OF AUTHORIZED ISSUE UNLIMITED NUMBER OF PAR VALUE SHARES (Details)", "shortName": "SCHEDULE OF AUTHORIZED ISSUE UNLIMITED NUMBER OF PAR VALUE SHARES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "AsOf2025-03-31", "name": "ifrs-full:Equity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2025-04-012026-03-31_custom_IssuedCapitalOrdinarySharesMember", "name": "OKYO:ExpensesSettledInShares", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "unique": true } }, "R65": { "role": "http://okyopharma.com/role/CapitalAndReservesDetailsNarrative", "longName": "999070 - Disclosure - CAPITAL AND RESERVES (Details Narrative)", "shortName": "CAPITAL AND RESERVES (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:DividendsPaidOrdinaryShares", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "span", "p", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:DividendsPaidOrdinaryShares", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "span", "p", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R66": { "role": "http://okyopharma.com/role/ScheduleOfOptionsOutstandingAndWeightedAverageExercisePriceDetails", "longName": "999071 - Disclosure - SCHEDULE OF OPTIONS OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE (Details)", "shortName": "SCHEDULE OF OPTIONS OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "AsOf2025-03-31", "name": "ifrs-full:NumberOfOutstandingShareOptions", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "OKYO:DisclosureOfDetailedInformationAboutOptionsOutstandingAndWeightedAverageExercisePriceExplanatory", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-03-31", "name": "ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "OKYO:DisclosureOfDetailedInformationAboutOptionsOutstandingAndWeightedAverageExercisePriceExplanatory", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "unique": true } }, "R67": { "role": "http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative", "longName": "999072 - Disclosure - SHARE OPTIONS AND WARRANTS (Details Narrative)", "shortName": "SHARE OPTIONS AND WARRANTS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "AsOf2026-03-31", "name": "ifrs-full:DeemedCostOfInvestmentsForWhichDeemedCostIsFairValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2026-03-31", "name": "ifrs-full:DeemedCostOfInvestmentsForWhichDeemedCostIsFairValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R68": { "role": "http://okyopharma.com/role/ScheduleOfShareOptionsOutstandingExpiryDatesAndExercisePricesDetails", "longName": "999073 - Disclosure - SCHEDULE OF SHARE OPTIONS OUTSTANDING EXPIRY DATES AND EXERCISE PRICES (Details)", "shortName": "SCHEDULE OF SHARE OPTIONS OUTSTANDING EXPIRY DATES AND EXERCISE PRICES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "From2026-02-102026-02-10", "name": "ifrs-full:ExercisePriceShareOptionsGranted2019", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "OKYO:DisclosureOfDetailedInformationAboutShareBasedPaymentAwardModelInputsOptionsGrantedExplanatory", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2025-04-012026-03-31_custom_MarchFourteenTwoThousandTwentyThreeMember", "name": "OKYO:ExpirationDateOfOutstanding", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "unique": true } }, "R69": { "role": "http://okyopharma.com/role/ScheduleOfShareBasedPaymentAwardModelInputsOptionsGrantedDetails", "longName": "999074 - Disclosure - SCHEDULE OF SHARE BASED PAYMENT AWARD MODEL INPUTS OPTIONS GRANTED (Details)", "shortName": "SCHEDULE OF SHARE BASED PAYMENT AWARD MODEL INPUTS OPTIONS GRANTED (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "From2026-02-102026-02-10", "name": "OKYO:GrantDateShareOptionsGranted2019", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "OKYO:DisclosureOfDetailedInformationAboutShareBasedPaymentAwardModelInputsOptionsGrantedExplanatory", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2026-02-102026-02-10", "name": "OKYO:GrantDateShareOptionsGranted2019", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "OKYO:DisclosureOfDetailedInformationAboutShareBasedPaymentAwardModelInputsOptionsGrantedExplanatory", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R70": { "role": "http://okyopharma.com/role/ScheduleOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails", "longName": "999075 - Disclosure - SCHEDULE OF WARRANTS OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE (Details)", "shortName": "SCHEDULE OF WARRANTS OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "AsOf2025-03-31_ifrs-full_WarrantReserveMember", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-31_ifrs-full_WarrantReserveMember", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "unique": true } }, "R71": { "role": "http://okyopharma.com/role/SummaryOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails", "longName": "999076 - Disclosure - SUMMARY OF FINANCIAL LIABILITIES BASED ON CONTRACTUAL UNDISCOUNTED PAYMENTS (Details)", "shortName": "SUMMARY OF FINANCIAL LIABILITIES BASED ON CONTRACTUAL UNDISCOUNTED PAYMENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "AsOf2026-03-31", "name": "ifrs-full:TradeAndOtherPayables", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "OKYO:DisclosureOfDetailedInformationOfMaturitiesOfFinancialInstrumentsExplanatory", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2026-03-31", "name": "ifrs-full:TradeAndOtherPayables", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "OKYO:DisclosureOfDetailedInformationOfMaturitiesOfFinancialInstrumentsExplanatory", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R72": { "role": "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative", "longName": "999077 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)", "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:SettlementOfLiabilitiesOnBehalfOfEntityByRelatedPartyRelatedPartyTransactions", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:SettlementOfLiabilitiesOnBehalfOfEntityByRelatedPartyRelatedPartyTransactions", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R73": { "role": "http://okyopharma.com/role/SummaryOfIncomeAndShareDataUsedInBasicAndDilutedLossPerShareComputationsDetails", "longName": "999078 - Disclosure - SUMMARY OF INCOME AND SHARE DATA USED IN THE BASIC AND DILUTED LOSS PER SHARE COMPUTATIONS (Details)", "shortName": "SUMMARY OF INCOME AND SHARE DATA USED IN THE BASIC AND DILUTED LOSS PER SHARE COMPUTATIONS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ifrs-full:EarningsPerShareExplanatory", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ifrs-full:EarningsPerShareExplanatory", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R74": { "role": "http://okyopharma.com/role/ScheduleOfContractualMaturitiesOfLeaseLiabilitiesDetails", "longName": "999079 - Disclosure - SCHEDULE OF CONTRACTUAL MATURITIES OF LEASE LIABILITIES (Details)", "shortName": "SCHEDULE OF CONTRACTUAL MATURITIES OF LEASE LIABILITIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "AsOf2026-03-31_ifrs-full_NotLaterThanOneYearMember", "name": "ifrs-full:GrossLeaseLiabilities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "OKYO:DisclosureOfDetailedInformationAboutContractualMaturitiesOfLeaseLiabilitiesExplanatory", "ifrs-full:DisclosureOfLeasesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2026-03-31_ifrs-full_NotLaterThanOneYearMember", "name": "ifrs-full:GrossLeaseLiabilities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "OKYO:DisclosureOfDetailedInformationAboutContractualMaturitiesOfLeaseLiabilitiesExplanatory", "ifrs-full:DisclosureOfLeasesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R75": { "role": "http://okyopharma.com/role/ScheduleOfCompanyAuditorsFeesDetails", "longName": "999080 - Disclosure - SCHEDULE OF COMPANY AUDITORS FEES (Details)", "shortName": "SCHEDULE OF COMPANY AUDITORS FEES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "ifrs-full:AuditorsRemuneration", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "OKYO:DisclosureOfDetailedInformationAboutOperatingExpensesExplanatory", "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2025-04-012026-03-31_custom_PKFLittlejohnLLPMember", "name": "ifrs-full:AuditorsRemunerationForAuditServices", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "OKYO:DisclosureOfDetailedInformationAboutCompanyAuditorsFeesExplanatory", "ifrs-full:DisclosureOfAuditorsRemunerationExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "unique": true } }, "R76": { "role": "http://okyopharma.com/role/ScheduleOfCashAndCashEquivalentDetails", "longName": "999081 - Disclosure - SCHEDULE OF CASH AND CASH EQUIVALENT (Details)", "shortName": "SCHEDULE OF CASH AND CASH EQUIVALENT (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "AsOf2026-03-31", "name": "ifrs-full:CashOnHand", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "OKYO:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2026-03-31", "name": "ifrs-full:CashOnHand", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "OKYO:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R77": { "role": "http://okyopharma.com/role/ScheduleOfShortTermInvestmentsDetails", "longName": "999082 - Disclosure - SCHEDULE OF SHORT TERM INVESTMENTS (Details)", "shortName": "SCHEDULE OF SHORT TERM INVESTMENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "AsOf2026-03-31", "name": "ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "OKYO:DisclosureOfDetailedInformationAboutShortTermInvestmentsExplanatory", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2026-03-31", "name": "ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "OKYO:DisclosureOfDetailedInformationAboutShortTermInvestmentsExplanatory", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R78": { "role": "http://okyopharma.com/role/ConvertibleLoanInstrumentsDetailsNarrative", "longName": "999083 - Disclosure - CONVERTIBLE LOAN INSTRUMENTS (Details Narrative)", "shortName": "CONVERTIBLE LOAN INSTRUMENTS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "From2025-10-292025-10-29", "name": "OKYO:SharesIssuedOnConvertibleDebtConversionShares", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "OKYO:DisclosureOfConvertibleLoanInstrumentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true }, "uniqueAnchor": null }, "R79": { "role": "http://okyopharma.com/role/ScheduleOfMilestonesPaymentDetails", "longName": "999084 - Disclosure - SCHEDULE OF MILESTONES PAYMENT (Details)", "shortName": "SCHEDULE OF MILESTONES PAYMENT (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "From2025-04-012026-03-31_custom_PhaseIHumanClinicalTrialMember", "name": "OKYO:AmountOfLicensedProductOrService", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "OKYO:DisclosureOfDetailedInformationAboutMilestonesPaymentExplanatory", "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-012026-03-31_custom_PhaseIHumanClinicalTrialMember", "name": "OKYO:AmountOfLicensedProductOrService", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "OKYO:DisclosureOfDetailedInformationAboutMilestonesPaymentExplanatory", "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } }, "R80": { "role": "http://okyopharma.com/role/CommitmentsAndContingenciesDetailsNarrative", "longName": "999085 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)", "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "OKYO:AnnualLicenseMaintenanceFee", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "td", "tr", "table", "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-04-01to2026-03-31", "name": "OKYO:AnnualLicenseMaintenanceFee", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "td", "tr", "table", "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "form20-f.htm", "first": true, "unique": true } } }, "tag": { "OKYO_AccountingPolicyAbstract": { "xbrltype": "stringItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "AccountingPolicyAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies" } } }, "auth_ref": [] }, "ifrs-full_Accruals": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Accruals", "crdr": "credit", "calculation": { "http://okyopharma.com/role/ScheduleOfTradeAndOtherPayablesDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentPayables", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://okyopharma.com/role/ScheduleOfTradeAndOtherPayablesDetails" ], "lang": { "en-us": { "role": { "label": "Accruals" } }, "en": { "role": { "documentation": "The amount of liabilities to pay for goods or services that have been received or supplied but have not been paid, invoiced or formally agreed with the supplier, including amounts due to employees." } } }, "auth_ref": [ "r346" ] }, "OKYO_AccruedInterestOnBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "AccruedInterestOnBorrowings", "crdr": "credit", "presentation": [ "http://okyopharma.com/role/ConvertibleLoanInstrumentsDetailsNarrative", "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accrued interest", "documentation": "Accrued interest on borrowings." } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r278" ] }, "OKYO_AdditionalBorrowingsInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "AdditionalBorrowingsInterestRate", "presentation": [ "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Additional interest rate", "documentation": "Additional borrowings interest rate." } } }, "auth_ref": [] }, "OKYO_AdditionalShorttermCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "AdditionalShorttermCreditFacilityMember", "presentation": [ "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Additional shortterm credit facility [member]", "documentation": "Additional shortterm credit facility [member]" } } }, "auth_ref": [] }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Additions" } }, "en": { "role": { "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Property, plant and equipment]" } } }, "auth_ref": [ "r6", "r112" ] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AddressTypeDomain", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r284" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r284" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r284" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r284" ] }, "OKYO_AdjustmentsForChangeInFairValueOfForfeitureOfOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "AdjustmentsForChangeInFairValueOfForfeitureOfOptions", "crdr": "credit", "calculation": { "http://okyopharma.com/role/StatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://okyopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Forfeiture of options", "documentation": "Adjustments for change in fair value of forfeiture of options.", "label": "AdjustmentsForChangeInFairValueOfForfeitureOfOptions" } } }, "auth_ref": [] }, "OKYO_AdjustmentsForChangeInFairValueOfWarrantCharge": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "AdjustmentsForChangeInFairValueOfWarrantCharge", "crdr": "credit", "calculation": { "http://okyopharma.com/role/StatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://okyopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Warrant charge", "documentation": "Adjustments for change in fair value of warrant charge.", "label": "AdjustmentsForChangeInFairValueOfWarrantCharge" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForCurrentTaxOfPriorPeriod", "crdr": "debit", "presentation": [ "http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetails" ], "lang": { "en-us": { "role": { "label": "Adjustments in respect of prior periods" } } }, "auth_ref": [ "r172", "r203" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables", "crdr": "debit", "calculation": { "http://okyopharma.com/role/StatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://okyopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net (increase)/decrease in operating assets/other receivables" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]" } } }, "auth_ref": [ "r335" ] }, "ifrs-full_AdjustmentsForDepreciationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDepreciationExpense", "crdr": "debit", "calculation": { "http://okyopharma.com/role/StatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://okyopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation of fixed assets" } }, "en": { "role": { "documentation": "Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r335" ] }, "ifrs-full_AdjustmentsForIncomeTaxExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForIncomeTaxExpense", "crdr": "debit", "calculation": { "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "negatedLabel": "Income tax", "label": "Adjustments for income tax expense" } } }, "auth_ref": [ "r32" ] }, "OKYO_AdjustmentsForIncreaseDecreaseInRelatedPartyPayables": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "AdjustmentsForIncreaseDecreaseInRelatedPartyPayables", "crdr": "debit", "calculation": { "http://okyopharma.com/role/StatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://okyopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net increase/(decrease) in related party balances", "documentation": "Adjustments for increase decrease in related party payables." } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables", "crdr": "debit", "calculation": { "http://okyopharma.com/role/StatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://okyopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net increase/(decrease) in trade and other payables" } }, "en": { "role": { "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]" } } }, "auth_ref": [ "r335" ] }, "ifrs-full_AdjustmentsForReconcileProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForReconcileProfitLoss", "crdr": "debit", "calculation": { "http://okyopharma.com/role/StatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://okyopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash inflow from taxation" } } }, "auth_ref": [ "r29" ] }, "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForReconcileProfitLossAbstract", "presentation": [ "http://okyopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForSharebasedPayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForSharebasedPayments", "crdr": "debit", "calculation": { "http://okyopharma.com/role/StatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://okyopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Share option charge" } } }, "auth_ref": [ "r334" ] }, "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains", "crdr": "debit", "calculation": { "http://okyopharma.com/role/StatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://okyopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "(Gain)/Loss on foreign exchange" } } }, "auth_ref": [ "r181", "r334" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r245", "r256", "r270", "r296" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r248", "r259", "r273", "r299" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "auth_ref": [ "r284" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "auth_ref": [ "r291" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "auth_ref": [ "r249", "r260", "r274", "r291", "r300", "r304", "r312" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "auth_ref": [ "r310" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentDescription", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "OKYO_AmountOfLicensedProductOrService": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "AmountOfLicensedProductOrService", "crdr": "debit", "presentation": [ "http://okyopharma.com/role/ScheduleOfMilestonesPaymentDetails" ], "lang": { "en-us": { "role": { "label": "Amount of licensed product or service", "documentation": "Amount of Licensed Product or Service." } } }, "auth_ref": [] }, "ifrs-full_AmountsPayableRelatedPartyTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AmountsPayableRelatedPartyTransactions", "crdr": "credit", "presentation": [ "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Amounts payable related party transaction" } }, "en": { "role": { "documentation": "The amounts payable resulting from related party transactions. [Refer: Total for all related parties [member]]" } } }, "auth_ref": [ "r16", "r18", "r119" ] }, "ifrs-full_AmountsReceivableRelatedPartyTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AmountsReceivableRelatedPartyTransactions", "crdr": "debit", "calculation": { "http://okyopharma.com/role/ScheduleOfPrepaidExpensesAndOtherReceivablesDetails": { "parentTag": "ifrs-full_TradeAndOtherReceivables", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://okyopharma.com/role/ScheduleOfPrepaidExpensesAndOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Related Party receivable" } }, "en": { "role": { "documentation": "The amounts receivable resulting from related party transactions. [Refer: Total for all related parties [member]]" } } }, "auth_ref": [ "r16", "r18", "r119" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AnnualInformationForm", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r252" ] }, "OKYO_AnnualLicenseMaintenanceFee": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "AnnualLicenseMaintenanceFee", "crdr": "credit", "presentation": [ "http://okyopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Annual license maintenance fee", "documentation": "Annual license maintenance fee." } } }, "auth_ref": [] }, "OKYO_AnnualLicenseMaintenanceFeeTherafter": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "AnnualLicenseMaintenanceFeeTherafter", "crdr": "debit", "presentation": [ "http://okyopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Annual license maintenance fee, therafter", "documentation": "Annual license maintenance fee, therafter." } } }, "auth_ref": [] }, "ifrs-full_ApplicableTaxRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ApplicableTaxRate", "presentation": [ "http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetailsParanthetical" ], "lang": { "en-us": { "role": { "label": "Corporation tax rate" } }, "en": { "role": { "documentation": "The applicable income tax rate." } } }, "auth_ref": [ "r3", "r110" ] }, "ifrs-full_Assets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Assets", "crdr": "debit", "calculation": { "http://okyopharma.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://okyopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets" } }, "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r49", "r50", "r51", "r84", "r86", "r136", "r137", "r152" ] }, "ifrs-full_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AssetsAbstract", "presentation": [ "http://okyopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r252" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorFirmId", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r229", "r231", "r252" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorLocation", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r229", "r231", "r252" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorName", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r229", "r231", "r252" ] }, "dei_AuditorOpinionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorOpinionTextBlock", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Opinion [Text Block]" } } }, "auth_ref": [ "r326" ] }, "ifrs-full_AuditorsRemuneration": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AuditorsRemuneration", "crdr": "debit", "presentation": [ "http://okyopharma.com/role/ScheduleOfCompanyAuditorsFeesDetails", "http://okyopharma.com/role/ScheduleOfOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Auditor\u2019s Remuneration (refer to Note 19)", "verboseLabel": "Total auditor\u2019s remuneration" } } }, "auth_ref": [ "r341" ] }, "ifrs-full_AuditorsRemunerationForAuditServices": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AuditorsRemunerationForAuditServices", "crdr": "debit", "presentation": [ "http://okyopharma.com/role/ScheduleOfCompanyAuditorsFeesDetails" ], "lang": { "en-us": { "role": { "label": "Fees payable to the company\u2019s auditors for the audit of the parent company and consolidated financial statements" } } }, "auth_ref": [ "r341" ] }, "ifrs-full_AuditorsRemunerationForOtherServices": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AuditorsRemunerationForOtherServices", "crdr": "debit", "presentation": [ "http://okyopharma.com/role/ScheduleOfCompanyAuditorsFeesDetails" ], "lang": { "en-us": { "role": { "label": "Audit-related assurance services" } } }, "auth_ref": [ "r341" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Exercise Price" } } }, "auth_ref": [ "r307" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r308" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgDiscLineItems", "auth_ref": [ "r303" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r303" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method" } } }, "auth_ref": [ "r303" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r303" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r303" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined" } } }, "auth_ref": [ "r303" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AwardTypeAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]" } } }, "auth_ref": [] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Securities" } } }, "auth_ref": [ "r306" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r305" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r304" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r304" ] }, "ifrs-full_BasicEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BasicEarningsLossPerShare", "presentation": [ "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss", "http://okyopharma.com/role/SummaryOfIncomeAndShareDataUsedInBasicAndDilutedLossPerShareComputationsDetails" ], "lang": { "en-us": { "role": { "label": "Basic loss per share attributable to common shareholders", "verboseLabel": "Basic loss per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } } }, "auth_ref": [ "r21", "r22" ] }, "OKYO_BernardDenoyerMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "BernardDenoyerMember", "presentation": [ "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Bernard Denoyer [member]", "documentation": "Bernard Denoyer [member]" } } }, "auth_ref": [] }, "OKYO_BonusSettledInShares": { "xbrltype": "sharesItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "BonusSettledInShares", "presentation": [ "http://okyopharma.com/role/ScheduleOfAuthorizedIssueUnlimitedNumberOfParValueSharesDetails" ], "lang": { "en-us": { "role": { "label": "Bonus settled in shares", "documentation": "Bonus settled in shares." } } }, "auth_ref": [] }, "OKYO_BonusSettledInValue": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "BonusSettledInValue", "crdr": "credit", "presentation": [ "http://okyopharma.com/role/ScheduleOfAuthorizedIssueUnlimitedNumberOfParValueSharesDetails" ], "lang": { "en-us": { "role": { "label": "Bonus settled in value", "documentation": "Bonus settled in value." } } }, "auth_ref": [] }, "ifrs-full_BorrowingsByNameAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingsByNameAxis", "presentation": [ "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Borrowings by name [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r338" ] }, "ifrs-full_BorrowingsByNameDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingsByNameDomain", "presentation": [ "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en": { "role": { "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]" } } }, "auth_ref": [ "r338" ] }, "ifrs-full_BorrowingsInterestRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingsInterestRate", "presentation": [ "http://okyopharma.com/role/ConvertibleLoanInstrumentsDetailsNarrative", "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest rate" } }, "en": { "role": { "documentation": "The interest rate on borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r338" ] }, "ifrs-full_BottomOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BottomOfRangeMember", "presentation": [ "http://okyopharma.com/role/ScheduleOfShareBasedPaymentAwardModelInputsOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Bottom of range [member]" } }, "en": { "role": { "documentation": "This member stands for the bottom of a range." } } }, "auth_ref": [ "r33", "r52", "r62", "r71", "r106", "r183", "r184", "r338" ] }, "OKYO_BritishPoundSterlingMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "BritishPoundSterlingMember", "presentation": [ "http://okyopharma.com/role/ScheduleOfCashAndCashEquivalentDetails", "http://okyopharma.com/role/ScheduleOfShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "GBP [member]", "documentation": "GBP [member]" } } }, "auth_ref": [] }, "dei_BusinessContactMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "BusinessContactMember", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Business Contact [Member]", "documentation": "Business contact for the entity" } } }, "auth_ref": [ "r231", "r252" ] }, "OKYO_CapitalAndReservesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "CapitalAndReservesAbstract", "lang": { "en-us": { "role": { "label": "Capital And Reserves" } } }, "auth_ref": [] }, "OKYO_CashAndCashEquivalentAxis": { "xbrltype": "stringItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "CashAndCashEquivalentAxis", "presentation": [ "http://okyopharma.com/role/ScheduleOfCashAndCashEquivalentDetails", "http://okyopharma.com/role/ScheduleOfShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalent [axis]", "documentation": "Cash and cash equivalent [axis]" } } }, "auth_ref": [] }, "OKYO_CashAndCashEquivalentDomain": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "CashAndCashEquivalentDomain", "presentation": [ "http://okyopharma.com/role/ScheduleOfCashAndCashEquivalentDetails", "http://okyopharma.com/role/ScheduleOfShortTermInvestmentsDetails" ], "auth_ref": [] }, "ifrs-full_CashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashAndCashEquivalents", "crdr": "debit", "calculation": { "http://okyopharma.com/role/BalanceSheets": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://okyopharma.com/role/BalanceSheets", "http://okyopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "periodStartLabel": "Cash and cash equivalent, beginning of period", "periodEndLabel": "Cash and cash equivalent, end of period" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } } }, "auth_ref": [ "r34", "r45", "r107", "r150" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://okyopharma.com/role/StatementsOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://okyopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Cash flows from (used in) financing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations." } } }, "auth_ref": [ "r28", "r35" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "presentation": [ "http://okyopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://okyopharma.com/role/StatementsOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://okyopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Cash flows from (used in) investing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations." } } }, "auth_ref": [ "r28", "r35" ] }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "presentation": [ "http://okyopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivities", "calculation": { "http://okyopharma.com/role/StatementsOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://okyopharma.com/role/AccountingPoliciesDetailsNarrative", "http://okyopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "negatedLabel": "Net cash used in operating activities", "label": "Cash flows from (used in) operating activities" } } }, "auth_ref": [ "r28", "r35" ] }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "presentation": [ "http://okyopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "auth_ref": [] }, "ifrs-full_CashOnHand": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashOnHand", "crdr": "debit", "presentation": [ "http://okyopharma.com/role/ScheduleOfCashAndCashEquivalentDetails" ], "lang": { "en-us": { "role": { "label": "Cash at bank and in hand" } }, "en": { "role": { "documentation": "The amount of cash held by the entity. This does not include demand deposits." } } }, "auth_ref": [ "r336" ] }, "ifrs-full_CategoriesOfRelatedPartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfRelatedPartiesAxis", "presentation": [ "http://okyopharma.com/role/ScheduleOfShareOptionsGrantedToDirectorsDetails" ], "lang": { "en-us": { "role": { "label": "Categories of related parties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r17", "r120" ] }, "ifrs-full_CategoriesOfRelatedPartiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfRelatedPartiesDomain", "presentation": [ "http://okyopharma.com/role/ScheduleOfShareOptionsGrantedToDirectorsDetails" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used." } } }, "auth_ref": [ "r17", "r120" ] }, "OKYO_ChairmansBonus": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "ChairmansBonus", "crdr": "debit", "presentation": [ "http://okyopharma.com/role/ScheduleOfOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Chairman\u2019s bonus", "documentation": "Chairman bonus." } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r282" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CityAreaCode", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis", "presentation": [ "http://okyopharma.com/role/ScheduleOfEmployeesCostAndNumberOfEmployeesExplanatoryDetails" ], "lang": { "en-us": { "role": { "label": "Classes of intangible assets other than goodwill [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r26", "r124" ] }, "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillDomain", "presentation": [ "http://okyopharma.com/role/ScheduleOfEmployeesCostAndNumberOfEmployeesExplanatoryDetails" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used." } } }, "auth_ref": [ "r26", "r124" ] }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfPropertyPlantAndEquipmentAxis", "presentation": [ "http://okyopharma.com/role/DisclosureOfEstimatedUsefulLivesDetails", "http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Classes of property, plant and equipment [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r10", "r115" ] }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfPropertyPlantAndEquipmentDomain", "presentation": [ "http://okyopharma.com/role/DisclosureOfEstimatedUsefulLivesDetails", "http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'Classes of property, plant and equipment' axis if no other member is used." } } }, "auth_ref": [ "r10", "r115" ] }, "OKYO_ClnFeesSettledInShares": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "ClnFeesSettledInShares", "crdr": "debit", "calculation": { "http://okyopharma.com/role/StatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://okyopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CLN Fees settled in shares", "documentation": "Cln fees settled in shares." } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r283" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r283" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r288" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r287" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r289" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r286" ] }, "ifrs-full_ComponentsOfEquityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfEquityAxis", "presentation": [ "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative", "http://okyopharma.com/role/ScheduleOfAuthorizedIssueUnlimitedNumberOfParValueSharesDetails", "http://okyopharma.com/role/ScheduleOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails", "http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative", "http://okyopharma.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Components of equity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r147" ] }, "ifrs-full_ComponentsOfEquityDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfEquityDomain", "presentation": [ "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative", "http://okyopharma.com/role/ScheduleOfAuthorizedIssueUnlimitedNumberOfParValueSharesDetails", "http://okyopharma.com/role/ScheduleOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails", "http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative", "http://okyopharma.com/role/StatementsOfShareholdersEquity" ], "lang": { "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } } }, "auth_ref": [ "r147" ] }, "ifrs-full_ComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComprehensiveIncome", "crdr": "credit", "calculation": { "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss", "http://okyopharma.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss", "label": "Total comprehensive income" } }, "en": { "role": { "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners." } } }, "auth_ref": [ "r37", "r40", "r44", "r122", "r127", "r145", "r165", "r182" ] }, "ifrs-full_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComputerEquipmentMember", "presentation": [ "http://okyopharma.com/role/DisclosureOfEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "label": "Computer equipment [member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing computer equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r331" ] }, "dei_ContactPersonnelEmailAddress": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "ContactPersonnelEmailAddress", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Contact Personnel Email Address", "documentation": "Email address of contact personnel." } } }, "auth_ref": [] }, "dei_ContactPersonnelName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "ContactPersonnelName", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Contact Personnel Name", "documentation": "Name of contact personnel" } } }, "auth_ref": [] }, "OKYO_ConversionOfConvertibleLoanNoteIntoShares": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "ConversionOfConvertibleLoanNoteIntoShares", "crdr": "credit", "presentation": [ "http://okyopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Conversion of convertible loan note into shares", "documentation": "Conversion of convertible loan note into shares." } } }, "auth_ref": [] }, "OKYO_ConversionOfRelatedPartyLoanIntoShares": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "ConversionOfRelatedPartyLoanIntoShares", "crdr": "credit", "presentation": [ "http://okyopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Conversion of related party loan into shares", "documentation": "Conversion of related party loan into shares" } } }, "auth_ref": [] }, "OKYO_ConvertibleLoanInterestAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "ConvertibleLoanInterestAccrued", "crdr": "debit", "calculation": { "http://okyopharma.com/role/StatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://okyopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Convertible loan interest accrued", "documentation": "Convertible loan interest accrued." } } }, "auth_ref": [] }, "OKYO_ConvertibleLoanNoteInterestLiabilitySettledByIssuanceOfShares": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "ConvertibleLoanNoteInterestLiabilitySettledByIssuanceOfShares", "crdr": "credit", "presentation": [ "http://okyopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Convertible loan note interest liability settled by the issuance of shares", "documentation": "Convertible loan note interest liability settled by the issuance of shares." } } }, "auth_ref": [] }, "OKYO_ConvertibleLoanNoteReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "ConvertibleLoanNoteReserve", "crdr": "credit", "calculation": { "http://okyopharma.com/role/BalanceSheets": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://okyopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Convertible Loan Note Reserve", "documentation": "Convertible loan note reserve." } } }, "auth_ref": [] }, "OKYO_ConvertibleLoanNoteReserveMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "ConvertibleLoanNoteReserveMember", "presentation": [ "http://okyopharma.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Convertible loan note reserve [member]", "documentation": "Convertible loan note reserve [member]" } } }, "auth_ref": [] }, "OKYO_CorporateAndAdministrationMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "CorporateAndAdministrationMember", "presentation": [ "http://okyopharma.com/role/ScheduleOfEmployeesCostAndNumberOfEmployeesExplanatoryDetails" ], "lang": { "en-us": { "role": { "label": "Corporate and administration [member]", "documentation": "Corporate and administration [member]" } } }, "auth_ref": [] }, "ifrs-full_CounterpartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CounterpartiesAxis", "presentation": [ "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Counterparties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r79" ] }, "ifrs-full_CounterpartiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CounterpartiesDomain", "presentation": [ "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en": { "role": { "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used." } } }, "auth_ref": [ "r79" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CountryRegion", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "ifrs-full_CurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAssets", "crdr": "debit", "calculation": { "http://okyopharma.com/role/BalanceSheets": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://okyopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Current assets" } }, "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } } }, "auth_ref": [ "r41", "r155", "r182" ] }, "ifrs-full_CurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAssetsAbstract", "presentation": [ "http://okyopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "ifrs-full_CurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLiabilities", "crdr": "credit", "calculation": { "http://okyopharma.com/role/BalanceSheets": { "parentTag": "ifrs-full_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://okyopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } } }, "auth_ref": [ "r43", "r156", "r182" ] }, "ifrs-full_CurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLiabilitiesAbstract", "presentation": [ "http://okyopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "auth_ref": [] }, "ifrs-full_CurrentTaxExpenseIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentTaxExpenseIncome", "crdr": "debit", "presentation": [ "http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetails" ], "lang": { "en-us": { "role": { "label": "Current year tax charge" } } }, "auth_ref": [ "r171", "r202" ] }, "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods", "crdr": "debit", "presentation": [ "http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development tax credits claimed in respect of previous periods" } } }, "auth_ref": [ "r330" ] }, "OKYO_CurrentTaxationReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "CurrentTaxationReceivable", "crdr": "debit", "calculation": { "http://okyopharma.com/role/BalanceSheets": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://okyopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current taxation receivable", "documentation": "Current taxation receivable" } } }, "auth_ref": [] }, "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r239", "r322" ] }, "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]" } } }, "auth_ref": [ "r239", "r322" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]" } } }, "auth_ref": [ "r241", "r324" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r241", "r324" ] }, "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]" } } }, "auth_ref": [ "r234", "r317" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementProcessesIntegratedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Flag]" } } }, "auth_ref": [ "r235", "r318" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Text Block]" } } }, "auth_ref": [ "r235", "r318" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]" } } }, "auth_ref": [ "r233", "r316" ] }, "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Third Party Engaged [Flag]" } } }, "auth_ref": [ "r236", "r319" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]" } } }, "auth_ref": [ "r238", "r321" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]" } } }, "auth_ref": [ "r238", "r321" ] }, "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r239", "r322" ] }, "cyd_CybersecurityRiskRoleOfManagementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskRoleOfManagementTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Role of Management [Text Block]" } } }, "auth_ref": [ "r240", "r323" ] }, "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]" } } }, "auth_ref": [ "r237", "r320" ] }, "ifrs-full_DebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DebtSecurities", "crdr": "credit", "presentation": [ "http://okyopharma.com/role/ConvertibleLoanInstrumentsDetailsNarrative", "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt instruments issued" } }, "en": { "role": { "documentation": "The amount of instruments issued by the entity that represent indebtedness." } } }, "auth_ref": [ "r343" ] }, "ifrs-full_DeemedCostOfInvestmentsForWhichDeemedCostIsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DeemedCostOfInvestmentsForWhichDeemedCostIsFairValue", "crdr": "debit", "presentation": [ "http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Fair value charge of share option instruments deemed" } } }, "auth_ref": [ "r38" ] }, "ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences", "crdr": "debit", "presentation": [ "http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetails" ], "lang": { "en-us": { "role": { "label": "Origination and reversal of timing differences" } } }, "auth_ref": [ "r173", "r204" ] }, "ifrs-full_DefinedBenefitPlansAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DefinedBenefitPlansAxis", "presentation": [ "http://okyopharma.com/role/ScheduleOfKeyManagementPersonnelCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Defined benefit plans [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r12", "r117" ] }, "ifrs-full_DefinedBenefitPlansDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DefinedBenefitPlansDomain", "presentation": [ "http://okyopharma.com/role/ScheduleOfKeyManagementPersonnelCompensationDetails" ], "lang": { "en": { "role": { "documentation": "This member stands for post-employment benefit plans other than defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods. It also represents the standard value for the 'Defined benefit plans' axis if no other member is used." } } }, "auth_ref": [ "r12", "r117" ] }, "ifrs-full_DepreciationAndAmortisationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DepreciationAndAmortisationExpense", "crdr": "debit", "presentation": [ "http://okyopharma.com/role/ScheduleOfOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Depreciation" } }, "en": { "role": { "documentation": "The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives." } } }, "auth_ref": [ "r46", "r82", "r88", "r144", "r170", "r211" ] }, "ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory", "presentation": [ "http://okyopharma.com/role/AccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for fair value measurement. [Refer: At fair value [member]]" } } }, "auth_ref": [ "r342" ] }, "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory", "presentation": [ "http://okyopharma.com/role/AccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Financial instruments" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for financial instruments. [Refer: Classes of financial instruments [domain]]" } } }, "auth_ref": [ "r342" ] }, "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "presentation": [ "http://okyopharma.com/role/AccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Foreign currency translation" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for foreign currency translation." } } }, "auth_ref": [ "r342" ] }, "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory", "presentation": [ "http://okyopharma.com/role/AccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Impairment" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for the impairment of assets." } } }, "auth_ref": [ "r342" ] }, "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory", "presentation": [ "http://okyopharma.com/role/AccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Taxation" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for income tax." } } }, "auth_ref": [ "r342" ] }, "ifrs-full_DescriptionOfAccountingPolicyForInvestmentPropertyExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForInvestmentPropertyExplanatory", "presentation": [ "http://okyopharma.com/role/AccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Short-term investments" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for investment property. [Refer: Investment property]" } } }, "auth_ref": [ "r342" ] }, "OKYO_DescriptionOfAccountingPolicyForLeaseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "DescriptionOfAccountingPolicyForLeaseExplanatory", "presentation": [ "http://okyopharma.com/role/AccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Leases", "documentation": "Description of accounting policy for lease explanatory." } } }, "auth_ref": [] }, "OKYO_DescriptionOfAccountingPolicyForLicenseFeesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "DescriptionOfAccountingPolicyForLicenseFeesExplanatory", "presentation": [ "http://okyopharma.com/role/AccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "License fees", "documentation": "Description of accounting policy for license fees explanatory." } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://okyopharma.com/role/AccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Property, plant and equipment" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r342" ] }, "OKYO_DescriptionOfAccountingPolicyForResearchAndDevelopmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExplanatory", "presentation": [ "http://okyopharma.com/role/AccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "Description of accounting policy for research and development explanatory." } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory", "presentation": [ "http://okyopharma.com/role/AccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash and cash equivalents", "label": "Description of accounting policy for restricted cash and cash equivalents [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]" } } }, "auth_ref": [ "r342" ] }, "ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForSegmentReportingExplanatory", "presentation": [ "http://okyopharma.com/role/AccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Segment reporting" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for segment reporting." } } }, "auth_ref": [ "r342" ] }, "OKYO_DescriptionOfAccountingPolicyForShareCapitalExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "DescriptionOfAccountingPolicyForShareCapitalExplanatory", "presentation": [ "http://okyopharma.com/role/AccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Share capital", "documentation": "Description of accounting policy for share capital explanatory." } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory", "presentation": [ "http://okyopharma.com/role/AccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Share based payments" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Types of share-based payment arrangements [domain]]" } } }, "auth_ref": [ "r342" ] }, "ifrs-full_DescriptionOfAccountingPolicyForWarrantsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForWarrantsExplanatory", "presentation": [ "http://okyopharma.com/role/AccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Warrants" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for warrants. Warrants are financial instruments that give the holder the right to purchase ordinary shares." } } }, "auth_ref": [ "r342" ] }, "OKYO_DescriptionOfBorrowingInterestRates": { "xbrltype": "stringItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "DescriptionOfBorrowingInterestRates", "presentation": [ "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Description of borrowing interest rates", "documentation": "Description of borrowing interest rates." } } }, "auth_ref": [] }, "OKYO_DescriptionOfConvertibleLoanNotesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "DescriptionOfConvertibleLoanNotesExplanatory", "presentation": [ "http://okyopharma.com/role/AccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Convertible loan notes", "documentation": "Description of convertible loan notes explanatory." } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted", "presentation": [ "http://okyopharma.com/role/ScheduleOfShareBasedPaymentAwardModelInputsOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Risk free rate" } }, "en": { "role": { "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]" } } }, "auth_ref": [ "r73" ] }, "ifrs-full_DilutedEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DilutedEarningsLossPerShare", "presentation": [ "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss", "http://okyopharma.com/role/SummaryOfIncomeAndShareDataUsedInBasicAndDilutedLossPerShareComputationsDetails" ], "lang": { "en-us": { "role": { "label": "Diluted loss per share attributable to common shareholders", "verboseLabel": "Dilutive loss per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r21", "r22" ] }, "OKYO_DirectorsAndOtherOfficersMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "DirectorsAndOtherOfficersMember", "presentation": [ "http://okyopharma.com/role/ScheduleOfShareOptionsGrantedToDirectorsDetails" ], "lang": { "en-us": { "role": { "label": "Directors and other officers [member]", "documentation": "Directors and other officers [member]" } } }, "auth_ref": [] }, "OKYO_DirectorsFees": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "DirectorsFees", "crdr": "debit", "presentation": [ "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Directors fees", "documentation": "Directors fees." } } }, "auth_ref": [] }, "OKYO_DirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "DirectorsMember", "presentation": [ "http://okyopharma.com/role/ScheduleOfShareOptionsGrantedToDirectorsDetails" ], "lang": { "en-us": { "role": { "label": "Directors [member]", "documentation": "Directors [member]" } } }, "auth_ref": [] }, "OKYO_DirectorsSalaries": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "DirectorsSalaries", "crdr": "debit", "presentation": [ "http://okyopharma.com/role/ScheduleOfEmployeesCostAndNumberOfEmployeesExplanatoryDetails" ], "lang": { "en-us": { "role": { "label": "Directors\u2019 salaries", "documentation": "Directors salaries." } } }, "auth_ref": [] }, "OKYO_DisclosureConvertibleLoanInstrumentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "DisclosureConvertibleLoanInstrumentsAbstract", "lang": { "en-us": { "role": { "label": "Convertible Loan Instruments" } } }, "auth_ref": [] }, "OKYO_DisclosureCriticalAccountingJudgementsAndKeySourcesOfEstimationUncertainty": { "xbrltype": "textBlockItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "DisclosureCriticalAccountingJudgementsAndKeySourcesOfEstimationUncertainty", "presentation": [ "http://okyopharma.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertainty" ], "lang": { "en-us": { "role": { "label": "CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY", "documentation": "Disclosure critical accounting judgements and key sources of estimation uncertainty." } } }, "auth_ref": [] }, "OKYO_DisclosureCriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAbstract": { "xbrltype": "stringItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "DisclosureCriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAbstract", "lang": { "en-us": { "role": { "label": "Critical Accounting Judgements And Key Sources Of Estimation Uncertainty" } } }, "auth_ref": [] }, "OKYO_DisclosureEmployeesIncludingOfficersExecutiveAndNonexecutiveDirectorTable": { "xbrltype": "stringItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "DisclosureEmployeesIncludingOfficersExecutiveAndNonexecutiveDirectorTable", "presentation": [ "http://okyopharma.com/role/ScheduleOfEmployeesCostAndNumberOfEmployeesExplanatoryDetails" ], "lang": { "en-us": { "role": { "label": "DisclosureEmployeesIncludingOfficersExecutiveAndNonexecutiveDirectorTable [Table]" } } }, "auth_ref": [] }, "OKYO_DisclosureEmployeesIncludingOfficersExecutiveAndNonexecutiveDirectorsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "DisclosureEmployeesIncludingOfficersExecutiveAndNonexecutiveDirectorsAbstract", "lang": { "en-us": { "role": { "label": "Employees Including Officers Executive And Non-executive Directors" } } }, "auth_ref": [] }, "OKYO_DisclosureOfAccountingPoliciesBasisOfPresentationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "DisclosureOfAccountingPoliciesBasisOfPresentationExplanatory", "presentation": [ "http://okyopharma.com/role/AccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of preparation", "documentation": "Disclosure of accounting policies basis of presentation explanatory" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable", "presentation": [ "http://okyopharma.com/role/ScheduleOfContractualMaturitiesOfLeaseLiabilitiesDetails", "http://okyopharma.com/role/SummaryOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more, and more than, twelve months after reporting date." } } }, "auth_ref": [ "r154" ] }, "ifrs-full_DisclosureOfAuditorsRemunerationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfAuditorsRemunerationExplanatory", "presentation": [ "http://okyopharma.com/role/AuditorsRemuneration" ], "lang": { "en-us": { "role": { "label": "AUDITOR\u2019S REMUNERATION" } }, "en": { "role": { "documentation": "The disclosure of compensation to the entity's auditors." } } }, "auth_ref": [ "r339" ] }, "ifrs-full_DisclosureOfBasisOfConsolidationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfBasisOfConsolidationExplanatory", "presentation": [ "http://okyopharma.com/role/AccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of consolidation" } }, "en": { "role": { "documentation": "The disclosure of the basis used for consolidation." } } }, "auth_ref": [ "r339" ] }, "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfCashAndCashEquivalentsExplanatory", "presentation": [ "http://okyopharma.com/role/CashAndCashEquivalentsAndShortTermInvestments" ], "lang": { "en-us": { "role": { "label": "CASH AND CASH EQUIVALENTS AND SHORT TERM INVESTMENTS" } }, "en": { "role": { "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r339" ] }, "ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfChangesInAccountingPoliciesExplanatory", "presentation": [ "http://okyopharma.com/role/AccountingPolicies" ], "lang": { "en-us": { "role": { "label": "ACCOUNTING POLICIES" } }, "en": { "role": { "documentation": "The disclosure of changes made to accounting policies by the entity." } } }, "auth_ref": [ "r339" ] }, "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalExplanatory", "presentation": [ "http://okyopharma.com/role/CapitalAndReservesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF AUTHORIZED ISSUE UNLIMITED NUMBER OF PAR VALUE SHARES" } }, "en": { "role": { "documentation": "The disclosure of classes of share capital. [Refer: Classes of share capital [domain]]" } } }, "auth_ref": [ "r103", "r140", "r162" ] }, "ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "presentation": [ "http://okyopharma.com/role/CommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENCIES" } }, "en": { "role": { "documentation": "The disclosure of commitments and contingent liabilities. [Refer: Classes of contingent liabilities [domain]]" } } }, "auth_ref": [ "r339" ] }, "OKYO_DisclosureOfConvertibleLoanInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "DisclosureOfConvertibleLoanInstrumentsExplanatory", "presentation": [ "http://okyopharma.com/role/ConvertibleLoanInstruments" ], "lang": { "en-us": { "role": { "label": "CONVERTIBLE LOAN INSTRUMENTS", "documentation": "The disclosure of detailed information of convertible loan instruments explanatory." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDefinedBenefitPlansTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDefinedBenefitPlansTable", "presentation": [ "http://okyopharma.com/role/ScheduleOfKeyManagementPersonnelCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of defined benefit plans [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to defined benefit plans." } } }, "auth_ref": [ "r12", "r117" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable", "presentation": [ "http://okyopharma.com/role/ScheduleOfShareBasedPaymentAwardModelInputsOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of borrowings." } } }, "auth_ref": [ "r338" ] }, "OKYO_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory", "presentation": [ "http://okyopharma.com/role/CashAndCashEquivalentsAndShortTermInvestmentsTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF CASH AND CASH EQUIVALENT", "documentation": "The disclosure of detailed information about cash and cash equivalents." } } }, "auth_ref": [] }, "OKYO_DisclosureOfDetailedInformationAboutCompanyAuditorsFeesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "DisclosureOfDetailedInformationAboutCompanyAuditorsFeesExplanatory", "presentation": [ "http://okyopharma.com/role/AuditorsRemunerationTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF COMPANY AUDITORS FEES", "documentation": "The disclosure of detailed information about company auditors fees explanatory." } } }, "auth_ref": [] }, "OKYO_DisclosureOfDetailedInformationAboutContractualMaturitiesOfLeaseLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "DisclosureOfDetailedInformationAboutContractualMaturitiesOfLeaseLiabilitiesExplanatory", "presentation": [ "http://okyopharma.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF CONTRACTUAL MATURITIES OF LEASE LIABILITIES", "documentation": "The disclosure of detailed information about contractual maturities of lease liabilities explanatory." } } }, "auth_ref": [] }, "OKYO_DisclosureOfDetailedInformationAboutEmployeesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "DisclosureOfDetailedInformationAboutEmployeesExplanatory", "presentation": [ "http://okyopharma.com/role/EmployeesIncludingOfficersExecutiveAndNon-executiveDirectorsTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF EMPLOYEES COST AND NUMBER OF EMPLOYEES EXPLANATORY", "documentation": "Disclosure of detailed information about employees explanatory." } } }, "auth_ref": [] }, "OKYO_DisclosureOfDetailedInformationAboutMilestonesPaymentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "DisclosureOfDetailedInformationAboutMilestonesPaymentExplanatory", "presentation": [ "http://okyopharma.com/role/CommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF MILESTONES PAYMENT", "documentation": "The tabular disclosure of milestones payments." } } }, "auth_ref": [] }, "OKYO_DisclosureOfDetailedInformationAboutOperatingExpensesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "DisclosureOfDetailedInformationAboutOperatingExpensesExplanatory", "presentation": [ "http://okyopharma.com/role/OperatingExpensesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF OPERATING EXPENSES", "documentation": "Disclosure of detailed information about operating expenses explanatory." } } }, "auth_ref": [] }, "OKYO_DisclosureOfDetailedInformationAboutOptionsOutstandingAndWeightedAverageExercisePriceExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "DisclosureOfDetailedInformationAboutOptionsOutstandingAndWeightedAverageExercisePriceExplanatory", "presentation": [ "http://okyopharma.com/role/ShareOptionsAndWarrantsTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF OPTIONS OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE", "documentation": "The disclosure of detailed information about options outstanding and weighted average exercise price explanatory." } } }, "auth_ref": [] }, "OKYO_DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatory", "presentation": [ "http://okyopharma.com/role/TradeAndOtherPayablesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF TRADE AND OTHER PAYABLES", "documentation": "Disclosure of detailed information about payables and accrued liabilities explanatory." } } }, "auth_ref": [] }, "OKYO_DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivablesExplanatoryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivablesExplanatoryTextBlock", "presentation": [ "http://okyopharma.com/role/PrepaidExpensesAndOtherReceivablesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF PREPAID EXPENSES AND OTHER RECEIVABLES", "documentation": "Disclosure of Detailed Information About Prepaid Expenses and Other Receivables Explanatory [Text Block]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://okyopharma.com/role/PropertyPlantAndEquipmentTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF PROPERTY PLANT AND EQUIPMENT" } }, "en": { "role": { "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r10", "r115" ] }, "OKYO_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentLocatedOperatingSegmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentLocatedOperatingSegmentExplanatory", "presentation": [ "http://okyopharma.com/role/PropertyPlantAndEquipmentTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF PROPERTY PLANT AND EQUIPMENT LOCATED IN OPERATING SEGMENT", "documentation": "Disclosure of Detailed Information About Property Plant And Equipment Located Operating Segment Explanatory [Table Text Block]" } } }, "auth_ref": [] }, "OKYO_DisclosureOfDetailedInformationAboutShareBasedPaymentAwardModelInputsOptionsGrantedExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "DisclosureOfDetailedInformationAboutShareBasedPaymentAwardModelInputsOptionsGrantedExplanatory", "presentation": [ "http://okyopharma.com/role/ShareOptionsAndWarrantsTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF SHARE BASED PAYMENT AWARD MODEL INPUTS OPTIONS GRANTED", "documentation": "Disclosure of detailed information about share based payment award model inputs options granted explanatory." } } }, "auth_ref": [] }, "OKYO_DisclosureOfDetailedInformationAboutShortTermInvestmentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "DisclosureOfDetailedInformationAboutShortTermInvestmentsExplanatory", "presentation": [ "http://okyopharma.com/role/CashAndCashEquivalentsAndShortTermInvestmentsTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF SHORT TERM INVESTMENTS", "documentation": "The disclosure of detailed information about short term investments explanatory." } } }, "auth_ref": [] }, "OKYO_DisclosureOfDetailedInformationOfMaturitiesOfFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "DisclosureOfDetailedInformationOfMaturitiesOfFinancialInstrumentsExplanatory", "presentation": [ "http://okyopharma.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "label": "SUMMARY OF FINANCIAL LIABILITIES BASED ON CONTRACTUAL UNDISCOUNTED PAYMENTS", "documentation": "The disclosure of detailed information of maturities of financial instruments explanatory." } } }, "auth_ref": [] }, "OKYO_DisclosureOfDetailedInformationShareOptionsGrantedToDirectorsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "DisclosureOfDetailedInformationShareOptionsGrantedToDirectorsExplanatory", "presentation": [ "http://okyopharma.com/role/RemunerationOfKeyManagementPersonnelTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF SHARE OPTIONS GRANTED TO DIRECTORS", "documentation": "Disclosure of Detailed Information Share Options Granted to Directors Explanatory." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable", "presentation": [ "http://okyopharma.com/role/ConvertibleLoanInstrumentsDetailsNarrative", "http://okyopharma.com/role/ScheduleOfMilestonesPaymentDetails", "http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentLocatedInOperatingSegmentDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of disaggregation of revenue from contracts with customers [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the disaggregation of revenue from contracts with customers." } } }, "auth_ref": [ "r53", "r93" ] }, "ifrs-full_DisclosureOfEarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfEarningsPerShareExplanatory", "presentation": [ "http://okyopharma.com/role/BasicAndDilutedLossPerShare" ], "lang": { "en-us": { "role": { "label": "BASIC AND DILUTED LOSS PER SHARE" } }, "en": { "role": { "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r24" ] }, "ifrs-full_DisclosureOfEmployeeBenefitsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfEmployeeBenefitsExplanatory", "presentation": [ "http://okyopharma.com/role/RemunerationOfKeyManagementPersonnelTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF KEY MANAGEMENT PERSONNEL COMPENSATION" } }, "en": { "role": { "documentation": "The entire disclosure for employee benefits." } } }, "auth_ref": [ "r14" ] }, "OKYO_DisclosureOfEmployeeDetailsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "DisclosureOfEmployeeDetailsExplanatory", "presentation": [ "http://okyopharma.com/role/EmployeesIncludingOfficersExecutiveAndNon-executiveDirectors" ], "lang": { "en-us": { "role": { "label": "EMPLOYEES INCLUDING OFFICERS, EXECUTIVE AND NON-EXECUTIVE DIRECTORS", "documentation": "Disclosure of employee details explanatory." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfEntitysReportableSegmentsExplanatory", "lang": { "en-us": { "role": { "label": "Disclosure of entity's operating segments [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for operating segments." } } }, "auth_ref": [ "r91" ] }, "OKYO_DisclosureOfEstimatedUsefulLivesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "DisclosureOfEstimatedUsefulLivesExplanatory", "presentation": [ "http://okyopharma.com/role/AccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "DISCLOSURE OF ESTIMATED USEFUL LIVES", "documentation": "The tabular disclosure for estimated useful lives explanatory." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory", "presentation": [ "http://okyopharma.com/role/PostBalanceSheetEvents" ], "lang": { "en-us": { "role": { "label": "POST BALANCE SHEET EVENTS" } }, "en": { "role": { "documentation": "The entire disclosure for events after the reporting period." } } }, "auth_ref": [ "r0" ] }, "ifrs-full_DisclosureOfFinanceCostExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinanceCostExplanatory", "presentation": [ "http://okyopharma.com/role/FinanceIncomeAndCostsTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF FINANCE INCOME AND COSTS" } } }, "auth_ref": [ "r339" ] }, "ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinanceIncomeExpenseExplanatory", "presentation": [ "http://okyopharma.com/role/FinanceIncomeAndCosts" ], "lang": { "en-us": { "role": { "label": "FINANCE INCOME AND COSTS" } } }, "auth_ref": [ "r339" ] }, "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsExplanatory", "presentation": [ "http://okyopharma.com/role/FinancialInstruments" ], "lang": { "en-us": { "role": { "label": "FINANCIAL INSTRUMENTS" } }, "en": { "role": { "documentation": "The entire disclosure for financial instruments." } } }, "auth_ref": [ "r80" ] }, "ifrs-full_DisclosureOfGoingConcernExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfGoingConcernExplanatory", "presentation": [ "http://okyopharma.com/role/AccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Going Concern" } }, "en": { "role": { "documentation": "The disclosure of the entity's ability to continue as a going concern." } } }, "auth_ref": [ "r339" ] }, "OKYO_DisclosureOfIncomeTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "DisclosureOfIncomeTaxAbstract", "lang": { "en-us": { "role": { "verboseLabel": "Taxation" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIncomeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIncomeTaxExplanatory", "presentation": [ "http://okyopharma.com/role/Taxation" ], "lang": { "en-us": { "role": { "label": "TAXATION" } }, "en": { "role": { "documentation": "The entire disclosure for income taxes." } } }, "auth_ref": [ "r4" ] }, "ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "presentation": [ "http://okyopharma.com/role/RemunerationOfKeyManagementPersonnel" ], "lang": { "en-us": { "role": { "label": "REMUNERATION OF KEY MANAGEMENT PERSONNEL" } }, "en": { "role": { "documentation": "The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]" } } }, "auth_ref": [ "r339" ] }, "ifrs-full_DisclosureOfLeasesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfLeasesExplanatory", "presentation": [ "http://okyopharma.com/role/Leases" ], "lang": { "en-us": { "role": { "label": "LEASES" } }, "en": { "role": { "documentation": "The entire disclosure for leases." } } }, "auth_ref": [ "r58", "r59" ] }, "OKYO_DisclosureOfNatureOfBusinessExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "DisclosureOfNatureOfBusinessExplanatory", "presentation": [ "http://okyopharma.com/role/ReportingEntity" ], "lang": { "en-us": { "role": { "verboseLabel": "Reporting Entity", "documentation": "Disclosure of nature of business explanatory", "label": "DisclosureOfNatureOfBusinessExplanatory" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "presentation": [ "http://okyopharma.com/role/ShareOptionsAndWarrantsTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF WARRANTS OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE" } }, "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options)." } } }, "auth_ref": [ "r337" ] }, "ifrs-full_DisclosureOfOperatingSegmentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOperatingSegmentsExplanatory", "presentation": [ "http://okyopharma.com/role/SegmentalReporting" ], "lang": { "en-us": { "role": { "label": "SEGMENTAL REPORTING" } }, "en": { "role": { "documentation": "The disclosure of operating segments. [Refer: Operating segments [member]]" } } }, "auth_ref": [ "r84" ] }, "ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOtherOperatingExpenseExplanatory", "presentation": [ "http://okyopharma.com/role/OperatingExpenses" ], "lang": { "en-us": { "role": { "label": "OPERATING EXPENSES" } } }, "auth_ref": [ "r339" ] }, "OKYO_DisclosureOfPrepaidExpensesAndOtherReceivablesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "DisclosureOfPrepaidExpensesAndOtherReceivablesTextBlock", "presentation": [ "http://okyopharma.com/role/PrepaidExpensesAndOtherReceivables" ], "lang": { "en-us": { "role": { "label": "PREPAID EXPENSES AND OTHER RECEIVABLES", "documentation": "Disclosure of Prepaid Expenses And Other Receivables [Text Block]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://okyopharma.com/role/PropertyPlantAndEquipment" ], "lang": { "en-us": { "role": { "label": "PROPERTY, PLANT AND EQUIPMENT" } }, "en": { "role": { "documentation": "The entire disclosure for property, plant and equipment." } } }, "auth_ref": [ "r11" ] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentTable", "presentation": [ "http://okyopharma.com/role/DisclosureOfEstimatedUsefulLivesDetails", "http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of property, plant and equipment." } } }, "auth_ref": [ "r10", "r115" ] }, "ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory", "presentation": [ "http://okyopharma.com/role/ShareOptionsAndWarrantsTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF SHARE OPTIONS OUTSTANDING EXPIRY DATES AND EXERCISE PRICES" } }, "en": { "role": { "documentation": "The disclosure of the range of exercise prices for outstanding share options." } } }, "auth_ref": [ "r71" ] }, "ifrs-full_DisclosureOfRelatedPartyExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfRelatedPartyExplanatory", "presentation": [ "http://okyopharma.com/role/RelatedPartyTransactions" ], "lang": { "en-us": { "role": { "label": "RELATED PARTY TRANSACTIONS" } }, "en": { "role": { "documentation": "The entire disclosure for related parties." } } }, "auth_ref": [ "r19" ] }, "OKYO_DisclosureOfRelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "DisclosureOfRelatedPartyTransactionsAbstract", "auth_ref": [] }, "OKYO_DisclosureOfRelatedPartyTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "DisclosureOfRelatedPartyTransactionsTable", "presentation": [ "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "DisclosureOfRelatedPartyTransactionsTable [Table]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "presentation": [ "http://okyopharma.com/role/CapitalAndReserves" ], "lang": { "en-us": { "role": { "label": "CAPITAL AND RESERVES" } }, "en": { "role": { "documentation": "The entire disclosure for share capital, reserves and other equity interest." } } }, "auth_ref": [ "r105", "r141", "r163" ] }, "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory", "presentation": [ "http://okyopharma.com/role/ShareOptionsAndWarrants" ], "lang": { "en-us": { "role": { "label": "SHARE OPTIONS AND WARRANTS" } }, "en": { "role": { "documentation": "The entire disclosure for share-based payment arrangements." } } }, "auth_ref": [ "r64" ] }, "ifrs-full_DisclosureOfTaxReceivablesAndPayablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTaxReceivablesAndPayablesExplanatory", "presentation": [ "http://okyopharma.com/role/TaxationTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF TAX CREDIT PERIOD" } }, "en": { "role": { "documentation": "The disclosure of tax receivables and payables." } } }, "auth_ref": [ "r339" ] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract", "auth_ref": [] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable", "presentation": [ "http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements." } } }, "auth_ref": [ "r72", "r134" ] }, "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTradeAndOtherPayablesExplanatory", "presentation": [ "http://okyopharma.com/role/TradeAndOtherPayables" ], "lang": { "en-us": { "role": { "label": "TRADE AND OTHER PAYABLES" } }, "en": { "role": { "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]" } } }, "auth_ref": [ "r339" ] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable", "presentation": [ "http://okyopharma.com/role/ScheduleOfShareOptionsGrantedToDirectorsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of transactions between related parties [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to transactions between related parties." } } }, "auth_ref": [ "r17", "r120" ] }, "OKYO_DisclosurePrepaidExpensesAndOtherReceivablesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "DisclosurePrepaidExpensesAndOtherReceivablesAbstract", "lang": { "en-us": { "role": { "label": "Prepaid Expenses And Other Receivables", "verboseLabel": "Schedule Of Prepaid Expenses And Other Receivables" } } }, "auth_ref": [] }, "OKYO_DisclosureReportingEntityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "DisclosureReportingEntityAbstract", "lang": { "en-us": { "role": { "label": "Reporting Entity" } } }, "auth_ref": [] }, "ifrs-full_DisposalsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisposalsPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Disposals", "label": "Disposals, property, plant and equipment" } }, "en": { "role": { "documentation": "The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r7", "r113" ] }, "ifrs-full_DividendsPaidOrdinaryShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DividendsPaidOrdinaryShares", "crdr": "debit", "presentation": [ "http://okyopharma.com/role/CapitalAndReservesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Dividends paid" } }, "en": { "role": { "documentation": "The amount of dividends paid by the entity on ordinary shares. [Refer: Ordinary shares [member]]" } } }, "auth_ref": [ "r25", "r123" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentAccountingStandard", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r231" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentAnnualReport", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r229", "r231", "r252" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r229", "r231", "r252", "r292" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodEndDate", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodStartDate", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentQuarterlyReport", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r230" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentRegistrationStatement", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r218" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r231" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentShellCompanyReport", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r231" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentTransitionReport", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r277" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r221" ] }, "ifrs-full_EarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EarningsPerShareExplanatory", "presentation": [ "http://okyopharma.com/role/BasicAndDilutedLossPerShareTables" ], "lang": { "en-us": { "role": { "label": "SUMMARY OF INCOME AND SHARE DATA USED IN THE BASIC AND DILUTED LOSS PER SHARE COMPUTATIONS" } }, "en": { "role": { "documentation": "The disclosure of earnings per share." } } }, "auth_ref": [ "r21" ] }, "OKYO_EffectOfChargeInYearDepreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "EffectOfChargeInYearDepreciation", "crdr": "debit", "presentation": [ "http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Charge in year", "documentation": "Effect of charge in year depreciation." } } }, "auth_ref": [] }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "crdr": "debit", "presentation": [ "http://okyopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Exchange difference" } }, "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r30", "r31" ] }, "OKYO_EffectOfForeignExchangeDepreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "EffectOfForeignExchangeDepreciation", "crdr": "credit", "presentation": [ "http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Foreign exchange", "documentation": "Effect of foreign exchange depreciation.", "label": "EffectOfForeignExchangeDepreciation" } } }, "auth_ref": [] }, "ifrs-full_EmployeeBenefitsExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EmployeeBenefitsExpense", "crdr": "debit", "presentation": [ "http://okyopharma.com/role/ScheduleOfEmployeesCostAndNumberOfEmployeesExplanatoryDetails" ], "lang": { "en-us": { "role": { "label": "Total employee benefits expense" } } }, "auth_ref": [ "r100", "r144", "r170", "r211" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine1", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine2", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine3", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCityOrTown", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCountry", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressesAddressTypeAxis", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityAddressesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressesLineItems", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Addresses [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityAddressesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressesTable", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Addresses [Table]", "documentation": "Container of address information for the entity" } } }, "auth_ref": [ "r220" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r224" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r220" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityDomain", "presentation": [ "http://okyopharma.com/role/ScheduleOfCompanyAuditorsFeesDetails" ], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r220" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityExTransitionPeriod", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r329" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFileNumber", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFilerCategory", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r220" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r325" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityPrimarySicNumber", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r252" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r220" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityShellCompany", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r220" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntitySmallBusiness", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r220" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r220" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityVoluntaryFilers", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r327" ] }, "ifrs-full_Equity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Equity", "crdr": "credit", "calculation": { "http://okyopharma.com/role/BalanceSheets": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://okyopharma.com/role/BalanceSheets", "http://okyopharma.com/role/ScheduleOfAuthorizedIssueUnlimitedNumberOfParValueSharesDetails", "http://okyopharma.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total shareholders\u2019 equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity" } }, "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } } }, "auth_ref": [ "r36", "r39", "r49", "r50", "r51", "r121", "r126", "r136", "r137", "r143", "r152", "r159" ] }, "ifrs-full_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAbstract", "presentation": [ "http://okyopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Shareholders\u2019 Equity:" } } }, "auth_ref": [] }, "ifrs-full_EquityAndLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAndLiabilities", "crdr": "credit", "calculation": { "http://okyopharma.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://okyopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and shareholders\u2019 equity", "label": "Equity and liabilities" } }, "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } } }, "auth_ref": [ "r152" ] }, "ifrs-full_EquityAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAndLiabilitiesAbstract", "presentation": [ "http://okyopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY" } } }, "auth_ref": [] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r285" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r245", "r256", "r270", "r296" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r242", "r253", "r267", "r293" ] }, "OKYO_EuropeanMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "EuropeanMember", "presentation": [ "http://okyopharma.com/role/ScheduleOfCashAndCashEquivalentDetails", "http://okyopharma.com/role/ScheduleOfShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "European [member]", "documentation": "European [member]" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r291" ] }, "ifrs-full_ExercisePriceShareOptionsGranted2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExercisePriceShareOptionsGranted2019", "presentation": [ "http://okyopharma.com/role/ScheduleOfShareBasedPaymentAwardModelInputsOptionsGrantedDetails", "http://okyopharma.com/role/ScheduleOfShareOptionsOutstandingExpiryDatesAndExercisePricesDetails", "http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share options granted", "verboseLabel": "Exercise Price", "terseLabel": "Exercise share price" } }, "en": { "role": { "documentation": "The exercise price of share options granted." } } }, "auth_ref": [ "r73" ] }, "ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExpectedDividendAsPercentageShareOptionsGranted", "presentation": [ "http://okyopharma.com/role/ScheduleOfShareBasedPaymentAwardModelInputsOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Expected volatility" } }, "en": { "role": { "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted." } } }, "auth_ref": [ "r73" ] }, "OKYO_ExpensesSettledInShares": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "ExpensesSettledInShares", "crdr": "debit", "calculation": { "http://okyopharma.com/role/StatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://okyopharma.com/role/ScheduleOfAuthorizedIssueUnlimitedNumberOfParValueSharesDetails", "http://okyopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Expenses settled in shares", "documentation": "Expenses settled in shares.", "label": "ExpensesSettledInShares" } } }, "auth_ref": [] }, "OKYO_ExpensesSettledInValue": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "ExpensesSettledInValue", "crdr": "credit", "presentation": [ "http://okyopharma.com/role/ScheduleOfAuthorizedIssueUnlimitedNumberOfParValueSharesDetails" ], "lang": { "en-us": { "role": { "label": "Expenses settled in shares, value", "documentation": "Expenses settled in value." } } }, "auth_ref": [] }, "OKYO_ExpirationDateOfOutstanding": { "xbrltype": "dateItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "ExpirationDateOfOutstanding", "presentation": [ "http://okyopharma.com/role/ScheduleOfShareOptionsOutstandingExpiryDatesAndExercisePricesDetails" ], "lang": { "en-us": { "role": { "label": "Expiration date of outstanding", "documentation": "Expiration date of outstanding." } } }, "auth_ref": [] }, "OKYO_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements": { "xbrltype": "textBlockItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements", "presentation": [ "http://okyopharma.com/role/AccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of measurement", "documentation": "Explanation of measurement bases used in preparing financial statements." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Extension", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "OKYO_FairValueOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "FairValueOfWarrants", "crdr": "debit", "presentation": [ "http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Fair value of warrants", "documentation": "Fair value of warrants." } } }, "auth_ref": [] }, "OKYO_FebruaryTenTwoThousandTwentySixMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "FebruaryTenTwoThousandTwentySixMember", "presentation": [ "http://okyopharma.com/role/ScheduleOfShareOptionsOutstandingExpiryDatesAndExercisePricesDetails" ], "lang": { "en-us": { "role": { "label": "February 10, 2026 [member]", "documentation": "February 10, 2026 [member]" } } }, "auth_ref": [] }, "OKYO_FeeAndShortTermEmployeeBenefitsMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "FeeAndShortTermEmployeeBenefitsMember", "presentation": [ "http://okyopharma.com/role/ScheduleOfKeyManagementPersonnelCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Fee and short term employee benefits [member]", "documentation": "Fee and short term employee benefits [member]" } } }, "auth_ref": [] }, "OKYO_FinanceCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "FinanceCharges", "crdr": "debit", "calculation": { "http://okyopharma.com/role/ScheduleOfFinanceIncomeAndCostsDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://okyopharma.com/role/ScheduleOfFinanceIncomeAndCostsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Finance Charges", "documentation": "Finance charges.", "label": "FinanceCharges" } } }, "auth_ref": [] }, "ifrs-full_FinanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceCosts", "crdr": "debit", "calculation": { "http://okyopharma.com/role/ScheduleOfFinanceIncomeAndCostsDetails": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://okyopharma.com/role/ScheduleOfFinanceIncomeAndCostsDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total finance expenses", "label": "Finance costs" } } }, "auth_ref": [ "r166" ] }, "ifrs-full_FinanceIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceIncome", "crdr": "credit", "calculation": { "http://okyopharma.com/role/ScheduleOfFinanceIncomeAndCostsDetails": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://okyopharma.com/role/ScheduleOfFinanceIncomeAndCostsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total finance income", "label": "Finance income" } } }, "auth_ref": [ "r347" ] }, "ifrs-full_FinanceIncomeCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceIncomeCost", "crdr": "credit", "calculation": { "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 2.0 }, "http://okyopharma.com/role/ScheduleOfFinanceIncomeAndCostsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://okyopharma.com/role/ScheduleOfFinanceIncomeAndCostsDetails", "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Finance expense (net)", "totalLabel": "Total finance income/(expenses)" } } }, "auth_ref": [ "r347" ] }, "ifrs-full_FinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialLiabilities", "crdr": "credit", "calculation": { "http://okyopharma.com/role/SummaryOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://okyopharma.com/role/SummaryOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Financial liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Classes of financial instruments [domain]; Financial assets; Derivatives [member]]" } } }, "auth_ref": [ "r77" ] }, "OKYO_ForeignCurrencyTranslationReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "ForeignCurrencyTranslationReserve", "crdr": "credit", "calculation": { "http://okyopharma.com/role/BalanceSheets": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://okyopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Foreign currency translation reserve", "documentation": "Foreign currency translation reserve" } } }, "auth_ref": [] }, "OKYO_ForeignExchangeLossesGains": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "ForeignExchangeLossesGains", "crdr": "debit", "presentation": [ "http://okyopharma.com/role/ScheduleOfOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "label": "FX Gains and losses", "documentation": "Foreign exchange loss gain." } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r249", "r260", "r274", "r300" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r249", "r260", "r274", "r300" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r249", "r260", "r274", "r300" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r249", "r260", "r274", "r300" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r249", "r260", "r274", "r300" ] }, "OKYO_GabrieleCerroneMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "GabrieleCerroneMember", "presentation": [ "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Gabriele Cerrone [member]", "documentation": "Gabriele Cerrone [member]" } } }, "auth_ref": [] }, "ifrs-full_GeographicalAreasAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GeographicalAreasAxis", "presentation": [ "http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentLocatedInOperatingSegmentDetails" ], "lang": { "en-us": { "role": { "label": "Geographical areas [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r90", "r175", "r186", "r190", "r200" ] }, "ifrs-full_GeographicalAreasDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GeographicalAreasDomain", "presentation": [ "http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentLocatedInOperatingSegmentDetails" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used." } } }, "auth_ref": [ "r90", "r175", "r186", "r190", "r200" ] }, "OKYO_GrantDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "GrantDateAxis", "presentation": [ "http://okyopharma.com/role/ScheduleOfShareBasedPaymentAwardModelInputsOptionsGrantedDetails", "http://okyopharma.com/role/ScheduleOfShareOptionsOutstandingExpiryDatesAndExercisePricesDetails" ], "lang": { "en-us": { "role": { "label": "Grant Date [Axis]", "verboseLabel": "GrantDateAxis [Axis]", "documentation": "Grant Date Axis." } } }, "auth_ref": [] }, "OKYO_GrantDateDomain": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "GrantDateDomain", "presentation": [ "http://okyopharma.com/role/ScheduleOfShareBasedPaymentAwardModelInputsOptionsGrantedDetails", "http://okyopharma.com/role/ScheduleOfShareOptionsOutstandingExpiryDatesAndExercisePricesDetails" ], "auth_ref": [] }, "OKYO_GrantDateShareOptionsGranted2019": { "xbrltype": "perShareItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "GrantDateShareOptionsGranted2019", "presentation": [ "http://okyopharma.com/role/ScheduleOfShareBasedPaymentAwardModelInputsOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Grant date share price", "documentation": "Grant date share options granted." } } }, "auth_ref": [] }, "OKYO_GrantFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "GrantFiveMember", "presentation": [ "http://okyopharma.com/role/ScheduleOfShareBasedPaymentAwardModelInputsOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Grant five [member]", "documentation": "Grant five [member]" } } }, "auth_ref": [] }, "OKYO_GrantFourMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "GrantFourMember", "presentation": [ "http://okyopharma.com/role/ScheduleOfShareBasedPaymentAwardModelInputsOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Grant four [member]", "documentation": "Grant four [member]" } } }, "auth_ref": [] }, "OKYO_GrantOneMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "GrantOneMember", "presentation": [ "http://okyopharma.com/role/ScheduleOfShareBasedPaymentAwardModelInputsOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Grant one [member]", "documentation": "Grant one [member]" } } }, "auth_ref": [] }, "OKYO_GrantThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "GrantThreeMember", "presentation": [ "http://okyopharma.com/role/ScheduleOfShareBasedPaymentAwardModelInputsOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Grant three [member]", "documentation": "Grant three [member]" } } }, "auth_ref": [] }, "OKYO_GrantTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "GrantTwoMember", "presentation": [ "http://okyopharma.com/role/ScheduleOfShareBasedPaymentAwardModelInputsOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Grant two [member]", "documentation": "Grant two [member]" } } }, "auth_ref": [] }, "ifrs-full_GrossLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GrossLeaseLiabilities", "crdr": "credit", "presentation": [ "http://okyopharma.com/role/ScheduleOfContractualMaturitiesOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Within one year" } }, "en": { "role": { "documentation": "The amount of contractual undiscounted cash flows in relation to lease liabilities before deducting finance charges. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r55", "r95", "r193" ] }, "OKYO_ITEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "ITEquipmentMember", "presentation": [ "http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "IT equipment [member]", "documentation": "IT equipment [member]" } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r229", "r231", "r252" ] }, "OKYO_IfrsStatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "IfrsStatementLineItems", "presentation": [ "http://okyopharma.com/role/ConvertibleLoanInstrumentsDetailsNarrative", "http://okyopharma.com/role/DisclosureOfEstimatedUsefulLivesDetails", "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative", "http://okyopharma.com/role/ScheduleOfAuthorizedIssueUnlimitedNumberOfParValueSharesDetails", "http://okyopharma.com/role/ScheduleOfCashAndCashEquivalentDetails", "http://okyopharma.com/role/ScheduleOfCompanyAuditorsFeesDetails", "http://okyopharma.com/role/ScheduleOfContractualMaturitiesOfLeaseLiabilitiesDetails", "http://okyopharma.com/role/ScheduleOfEmployeesCostAndNumberOfEmployeesExplanatoryDetails", "http://okyopharma.com/role/ScheduleOfKeyManagementPersonnelCompensationDetails", "http://okyopharma.com/role/ScheduleOfMilestonesPaymentDetails", "http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentDetails", "http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentLocatedInOperatingSegmentDetails", "http://okyopharma.com/role/ScheduleOfShareBasedPaymentAwardModelInputsOptionsGrantedDetails", "http://okyopharma.com/role/ScheduleOfShareOptionsGrantedToDirectorsDetails", "http://okyopharma.com/role/ScheduleOfShareOptionsOutstandingExpiryDatesAndExercisePricesDetails", "http://okyopharma.com/role/ScheduleOfShortTermInvestmentsDetails", "http://okyopharma.com/role/ScheduleOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails", "http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative", "http://okyopharma.com/role/StatementsOfShareholdersEquity", "http://okyopharma.com/role/SummaryOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "IfrsStatementLineItems [Line Items]" } } }, "auth_ref": [] }, "OKYO_IfrsStatementTable": { "xbrltype": "stringItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "IfrsStatementTable", "presentation": [ "http://okyopharma.com/role/ScheduleOfCashAndCashEquivalentDetails", "http://okyopharma.com/role/ScheduleOfShareOptionsOutstandingExpiryDatesAndExercisePricesDetails", "http://okyopharma.com/role/ScheduleOfShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "IfrsStatementTable [Table]" } } }, "auth_ref": [] }, "ifrs-full_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Profit or loss [abstract]" } } }, "auth_ref": [] }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeTaxExpenseContinuingOperations", "crdr": "debit", "presentation": [ "http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Total tax charge/(credit) for the period", "label": "Tax expense (income)" } } }, "auth_ref": [ "r1", "r2", "r3", "r20", "r48", "r83", "r108", "r109", "r110", "r167" ] }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://okyopharma.com/role/StatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://okyopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase/(decrease) in cash and cash equivalents", "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes" } }, "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } } }, "auth_ref": [ "r34", "r107" ] }, "OKYO_IncreaseDecreaseThroughCLNInterestSettledInShares": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "IncreaseDecreaseThroughCLNInterestSettledInShares", "crdr": "credit", "presentation": [ "http://okyopharma.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "CLN Interest settled in shares", "documentation": "Increase (decrease) through CLN interest settled in shares." } } }, "auth_ref": [] }, "OKYO_IncreaseDecreaseThroughCLNSettledInShares": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "IncreaseDecreaseThroughCLNSettledInShares", "crdr": "credit", "presentation": [ "http://okyopharma.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "CLN settled in Shares", "documentation": "Increase (decrease) through CLN settled in shares." } } }, "auth_ref": [] }, "OKYO_IncreaseDecreaseThroughExerciseOfForfeiture": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "IncreaseDecreaseThroughExerciseOfForfeiture", "crdr": "credit", "presentation": [ "http://okyopharma.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Options forfeiture", "documentation": "Increase decrease through exercise of forfeiture" } } }, "auth_ref": [] }, "OKYO_IncreaseDecreaseThroughExerciseOfWarrantsCharge": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "IncreaseDecreaseThroughExerciseOfWarrantsCharge", "crdr": "credit", "presentation": [ "http://okyopharma.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Warrants charge", "documentation": "Increase decrease through exercise of warrants charge" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughForeignExchangeFinancialAssets", "crdr": "debit", "presentation": [ "http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetails" ], "lang": { "en-us": { "role": { "label": "Consolidation adjustment in relation to foreign exchange movements" } }, "en": { "role": { "documentation": "The increase (decrease) in financial assets resulting from foreign exchange. [Refer: Financial assets]" } } }, "auth_ref": [ "r191", "r195", "r208" ] }, "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Foreign exchange" } }, "en": { "role": { "documentation": "The increase (decrease) in property, plant and equipment resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r8" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]" } } }, "auth_ref": [ "r249", "r260", "r274", "r291", "r300", "r304", "r312" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTradingArrLineItems", "auth_ref": [ "r310" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r232", "r315" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r232", "r315" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r232", "r315" ] }, "ifrs-full_InterestExpenseOnBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestExpenseOnBorrowings", "crdr": "debit", "calculation": { "http://okyopharma.com/role/ScheduleOfFinanceIncomeAndCostsDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://okyopharma.com/role/ScheduleOfFinanceIncomeAndCostsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Convertible Loan Note Interest", "label": "Interest expense on borrowings" } } }, "auth_ref": [ "r341" ] }, "OKYO_InterestExpenseOnRelatedPartyLoan": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "InterestExpenseOnRelatedPartyLoan", "crdr": "debit", "calculation": { "http://okyopharma.com/role/ScheduleOfFinanceIncomeAndCostsDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://okyopharma.com/role/ScheduleOfFinanceIncomeAndCostsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense on related party loan", "documentation": "Interest expense on related party loan.", "label": "Interest expense on related party loan" } } }, "auth_ref": [] }, "ifrs-full_IssuedCapitalMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssuedCapitalMember", "presentation": [ "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative", "http://okyopharma.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Issued capital [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } } }, "auth_ref": [ "r147" ] }, "OKYO_IssuedCapitalOrdinarySharesMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "IssuedCapitalOrdinarySharesMember", "presentation": [ "http://okyopharma.com/role/ScheduleOfAuthorizedIssueUnlimitedNumberOfParValueSharesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Issued capital [member]", "documentation": "Issued capital [member]", "label": "Issued capital [member] [Default Label]" } } }, "auth_ref": [] }, "OKYO_JanuaryTwentyNineTwoThousandTwentyFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "JanuaryTwentyNineTwoThousandTwentyFiveMember", "presentation": [ "http://okyopharma.com/role/ScheduleOfShareOptionsOutstandingExpiryDatesAndExercisePricesDetails" ], "lang": { "en-us": { "role": { "label": "January 29 ,2025 [member]", "documentation": "January 29 ,2025 [member]" } } }, "auth_ref": [] }, "OKYO_JanuaryTwoTwoThousandTwentySixMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "JanuaryTwoTwoThousandTwentySixMember", "presentation": [ "http://okyopharma.com/role/ScheduleOfShareOptionsOutstandingExpiryDatesAndExercisePricesDetails" ], "lang": { "en-us": { "role": { "label": "January 2, 2026 [member]", "documentation": "January 2, 2026 [member]" } } }, "auth_ref": [] }, "OKYO_JohnBrancaccioMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "JohnBrancaccioMember", "presentation": [ "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "John Brancaccio [member]", "documentation": "John Brancaccio [member]" } } }, "auth_ref": [] }, "OKYO_JulyTenTwoThousandTwentyFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "JulyTenTwoThousandTwentyFiveMember", "presentation": [ "http://okyopharma.com/role/ScheduleOfShareOptionsOutstandingExpiryDatesAndExercisePricesDetails" ], "lang": { "en-us": { "role": { "label": "July 10, 2025 [member]", "documentation": "July 10, 2025 [member]" } } }, "auth_ref": [] }, "ifrs-full_KeyManagementPersonnelCompensation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensation", "crdr": "debit", "presentation": [ "http://okyopharma.com/role/ScheduleOfKeyManagementPersonnelCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Total Key Management Personnel" } } }, "auth_ref": [ "r15", "r118" ] }, "OKYO_KeyManagementPersonnelCompensationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "KeyManagementPersonnelCompensationAbstract", "lang": { "en-us": { "role": { "label": "Remuneration Of Key Management Personnel" } } }, "auth_ref": [] }, "OKYO_KeyManagementPersonnelCompensationDirectorFees": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "KeyManagementPersonnelCompensationDirectorFees", "crdr": "debit", "presentation": [ "http://okyopharma.com/role/ScheduleOfOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Director fees including bonus (excluding Chairman\u2019s bonus)", "documentation": "Director fees." } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LegalEntityAxis", "presentation": [ "http://okyopharma.com/role/ScheduleOfCompanyAuditorsFeesDetails" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "OKYO_LessThanThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "LessThanThreeMember", "presentation": [ "http://okyopharma.com/role/SummaryOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Less than 3 months [member]", "documentation": "Less than 3 months [member]" } } }, "auth_ref": [] }, "ifrs-full_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://okyopharma.com/role/BalanceSheets": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://okyopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities" } }, "en": { "role": { "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r49", "r50", "r51", "r84", "r87", "r136", "r137", "r152" ] }, "ifrs-full_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LiabilitiesAbstract", "presentation": [ "http://okyopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities:" } } }, "auth_ref": [] }, "OKYO_LineOfCreditFacilityMaximumBorrowingsCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "LineOfCreditFacilityMaximumBorrowingsCapacity", "crdr": "credit", "presentation": [ "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Maximum borrowing capacity amount", "documentation": "Line of credit facility maximum borrowings capacity." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LocalPhoneNumber", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "OKYO_LossBeforeTaxation": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "LossBeforeTaxation", "crdr": "credit", "presentation": [ "http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetails" ], "lang": { "en-us": { "role": { "label": "Loss before taxation", "documentation": "Loss before taxation." } } }, "auth_ref": [] }, "OKYO_LossChargedAtStandardRateOfCorporationTax": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "LossChargedAtStandardRateOfCorporationTax", "crdr": "credit", "presentation": [ "http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetails" ], "lang": { "en-us": { "role": { "label": "Loss charged at standard rate of corporation tax 19%", "documentation": "Loss charged at standard rate of corporation tax." } } }, "auth_ref": [] }, "OKYO_MarchFourteenTwoThousandTwentyThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "MarchFourteenTwoThousandTwentyThreeMember", "presentation": [ "http://okyopharma.com/role/ScheduleOfShareOptionsOutstandingExpiryDatesAndExercisePricesDetails" ], "lang": { "en-us": { "role": { "label": "March 14, 2023 [member]", "documentation": "March 14, 2023 [member]" } } }, "auth_ref": [] }, "OKYO_MarchOneTwoThousandTwentyFourMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "MarchOneTwoThousandTwentyFourMember", "presentation": [ "http://okyopharma.com/role/ScheduleOfShareOptionsOutstandingExpiryDatesAndExercisePricesDetails" ], "lang": { "en-us": { "role": { "label": "March 1, 2024 [member]", "documentation": "March 1, 2024 [member]" } } }, "auth_ref": [] }, "OKYO_MarchThirteenTwoThousandTwentyFourMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "MarchThirteenTwoThousandTwentyFourMember", "presentation": [ "http://okyopharma.com/role/ScheduleOfShareOptionsOutstandingExpiryDatesAndExercisePricesDetails" ], "lang": { "en-us": { "role": { "label": "March 13, 2024 [member]", "documentation": "March 13, 2024 [member]" } } }, "auth_ref": [] }, "OKYO_MarchTwentyEightTwoThousandTwentyFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "MarchTwentyEightTwoThousandTwentyFiveMember", "presentation": [ "http://okyopharma.com/role/ScheduleOfShareOptionsOutstandingExpiryDatesAndExercisePricesDetails" ], "lang": { "en-us": { "role": { "label": "March 28, 2025 [member]", "documentation": "March 28, 2025 [member]" } } }, "auth_ref": [] }, "cyd_MaterialCybersecurityIncidentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "MaterialCybersecurityIncidentAbstract", "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident [Abstract]" } } }, "auth_ref": [ "r263", "r264" ] }, "cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" ], "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]" } } }, "auth_ref": [ "r263", "r265" ] }, "cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" ], "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]" } } }, "auth_ref": [ "r263", "r266" ] }, "cyd_MaterialCybersecurityIncidentNatureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "MaterialCybersecurityIncidentNatureTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" ], "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident Nature [Text Block]" } } }, "auth_ref": [ "r263", "r266" ] }, "cyd_MaterialCybersecurityIncidentScopeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "MaterialCybersecurityIncidentScopeTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" ], "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident Scope [Text Block]" } } }, "auth_ref": [ "r263", "r266" ] }, "cyd_MaterialCybersecurityIncidentTimingTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "MaterialCybersecurityIncidentTimingTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" ], "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident Timing [Text Block]" } } }, "auth_ref": [ "r263", "r266" ] }, "ifrs-full_MaterialIncomeAndExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MaterialIncomeAndExpenseAbstract", "presentation": [ "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "auth_ref": [] }, "ifrs-full_MaturityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MaturityAxis", "presentation": [ "http://okyopharma.com/role/ScheduleOfContractualMaturitiesOfLeaseLiabilitiesDetails", "http://okyopharma.com/role/SummaryOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Maturity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r54", "r56", "r57", "r60", "r61", "r62", "r63", "r76", "r78", "r92", "r94", "r97", "r99", "r135", "r154", "r176", "r192" ] }, "ifrs-full_MaturityDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MaturityDomain", "presentation": [ "http://okyopharma.com/role/ScheduleOfContractualMaturitiesOfLeaseLiabilitiesDetails", "http://okyopharma.com/role/SummaryOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used." } } }, "auth_ref": [ "r54", "r56", "r57", "r60", "r61", "r62", "r63", "r76", "r92", "r94", "r97", "r99", "r135", "r154", "r176", "r192", "r194" ] }, "OKYO_MazarsLLPMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "MazarsLLPMember", "presentation": [ "http://okyopharma.com/role/ScheduleOfCompanyAuditorsFeesDetails" ], "lang": { "en-us": { "role": { "label": "Mazars LLP [member]", "documentation": "Mazars LLP [member]" } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]" } } }, "auth_ref": [ "r283" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Name" } } }, "auth_ref": [ "r283" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r303" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r311" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r284" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss)" } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "NoTradingSymbolFlag", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "OKYO_NonCashItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "NonCashItemsAbstract", "presentation": [ "http://okyopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Non Cash items:", "documentation": "Non cash items abstract" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r283" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r281" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r280" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r311" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r311" ] }, "ifrs-full_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentAssets", "crdr": "debit", "calculation": { "http://okyopharma.com/role/BalanceSheets": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://okyopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total non-current assets", "label": "Non-current assets" } }, "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } } }, "auth_ref": [ "r42", "r155", "r182" ] }, "ifrs-full_NotLaterThanOneYearMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NotLaterThanOneYearMember", "presentation": [ "http://okyopharma.com/role/ScheduleOfContractualMaturitiesOfLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Not later than one year [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of not later than one year." } } }, "auth_ref": [ "r56", "r57", "r63", "r96", "r98", "r153", "r192", "r196" ] }, "ifrs-full_NotesAndOtherExplanatoryInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NotesAndOtherExplanatoryInformationAbstract", "lang": { "en-us": { "role": { "label": "Notes and other explanatory information [abstract]" } } }, "auth_ref": [] }, "OKYO_NovemberTwentyFourTwoThousandTwentyThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "NovemberTwentyFourTwoThousandTwentyThreeMember", "presentation": [ "http://okyopharma.com/role/ScheduleOfShareOptionsOutstandingExpiryDatesAndExercisePricesDetails" ], "lang": { "en-us": { "role": { "label": "November 20, 2023 [member]", "documentation": "November 20, 2023\t [member]" } } }, "auth_ref": [] }, "ifrs-full_NumberOfEmployees": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfEmployees", "presentation": [ "http://okyopharma.com/role/ScheduleOfEmployeesCostAndNumberOfEmployeesExplanatoryDetails" ], "lang": { "en-us": { "role": { "label": "Total number of employees" } }, "en": { "role": { "documentation": "The number of personnel employed by the entity at a date." } } }, "auth_ref": [ "r341" ] }, "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted", "presentation": [ "http://okyopharma.com/role/ScheduleOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails" ], "lang": { "en-us": { "role": { "label": "Warrants granted" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement." } } }, "auth_ref": [ "r74", "r337" ] }, "OKYO_NumberOfIssueOfShareForFundraisingNet": { "xbrltype": "sharesItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "NumberOfIssueOfShareForFundraisingNet", "presentation": [ "http://okyopharma.com/role/ScheduleOfAuthorizedIssueUnlimitedNumberOfParValueSharesDetails" ], "lang": { "en-us": { "role": { "label": "Issue of Shares for fundraising, net, shares", "documentation": "Number of issue of shares for fundraising, net." } } }, "auth_ref": [] }, "ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement", "presentation": [ "http://okyopharma.com/role/ScheduleOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Warrants exercisable", "label": "Number of other equity instruments exercisable in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement." } } }, "auth_ref": [ "r337" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement", "presentation": [ "http://okyopharma.com/role/ScheduleOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails" ], "lang": { "en-us": { "role": { "label": "Warrants exercised" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement." } } }, "auth_ref": [ "r337" ] }, "OKYO_NumberOfOtherEquityInstrumentsGrantedOrExercisedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "NumberOfOtherEquityInstrumentsGrantedOrExercisedInSharebasedPaymentArrangement", "presentation": [ "http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of warrants granted or exercised", "documentation": "Number of other equity instruments granted or exercised in share based payment arrangement." } } }, "auth_ref": [] }, "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "presentation": [ "http://okyopharma.com/role/ScheduleOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Warrants outstanding, beginning balance", "periodEndLabel": "Warrants outstanding, ending balance", "label": "Number of other equity instruments outstanding in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement." } } }, "auth_ref": [ "r337" ] }, "ifrs-full_NumberOfOutstandingShareOptions": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOutstandingShareOptions", "presentation": [ "http://okyopharma.com/role/ScheduleOfOptionsOutstandingAndWeightedAverageExercisePriceDetails", "http://okyopharma.com/role/ScheduleOfShareOptionsOutstandingExpiryDatesAndExercisePricesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance, Options outstanding", "periodEndLabel": "Ending balance, Options outstanding", "label": "Share Options, Outstanding" } }, "en": { "role": { "documentation": "The number of share options outstanding in a share-based payment arrangement." } } }, "auth_ref": [ "r65", "r69", "r71", "r128", "r132" ] }, "OKYO_NumberOfShareInLieuInterest": { "xbrltype": "sharesItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "NumberOfShareInLieuInterest", "presentation": [ "http://okyopharma.com/role/ScheduleOfAuthorizedIssueUnlimitedNumberOfParValueSharesDetails" ], "lang": { "en-us": { "role": { "label": "Shares in lieu interest", "documentation": "Number of share in lieu interest." } } }, "auth_ref": [] }, "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement", "presentation": [ "http://okyopharma.com/role/ScheduleOfOptionsOutstandingAndWeightedAverageExercisePriceDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Options, Exercisable", "label": "Number of share options exercisable in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options exercisable in a share-based payment arrangement." } } }, "auth_ref": [ "r70", "r133" ] }, "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement", "presentation": [ "http://okyopharma.com/role/ScheduleOfOptionsOutstandingAndWeightedAverageExercisePriceDetails", "http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "negatedLabel": "Options, exercised", "label": "Number of option were exercised" } }, "en": { "role": { "documentation": "The number of share options exercised in a share-based payment arrangement." } } }, "auth_ref": [ "r68", "r131" ] }, "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement", "presentation": [ "http://okyopharma.com/role/ScheduleOfOptionsOutstandingAndWeightedAverageExercisePriceDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Options, forfeited", "label": "Number of share options forfeited in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options forfeited in a share-based payment arrangement." } } }, "auth_ref": [ "r67", "r130" ] }, "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "presentation": [ "http://okyopharma.com/role/ScheduleOfOptionsOutstandingAndWeightedAverageExercisePriceDetails", "http://okyopharma.com/role/ScheduleOfShareOptionsGrantedToDirectorsDetails" ], "lang": { "en-us": { "role": { "label": "Number of options", "verboseLabel": "Options, granted" } }, "en": { "role": { "documentation": "The number of share options granted in a share-based payment arrangement." } } }, "auth_ref": [ "r66", "r129" ] }, "OKYO_NumberOfSharesInLieuInterestValue": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "NumberOfSharesInLieuInterestValue", "crdr": "debit", "presentation": [ "http://okyopharma.com/role/ScheduleOfAuthorizedIssueUnlimitedNumberOfParValueSharesDetails" ], "lang": { "en-us": { "role": { "label": "Shares in lieu interest, value", "documentation": "Number of shares in lieu interest value." } } }, "auth_ref": [] }, "OKYO_NumberOfSharesIssueOfShareForFundraisingNetValue": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "NumberOfSharesIssueOfShareForFundraisingNetValue", "crdr": "credit", "presentation": [ "http://okyopharma.com/role/ScheduleOfAuthorizedIssueUnlimitedNumberOfParValueSharesDetails" ], "lang": { "en-us": { "role": { "label": "Issue of Shares for fundraising, net, value", "documentation": "Number of issue of shares for fundraising, net value." } } }, "auth_ref": [] }, "OKYO_NumberOfSharesIssuedCLNInterestSettledInSharesShares": { "xbrltype": "sharesItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "NumberOfSharesIssuedCLNInterestSettledInSharesShares", "presentation": [ "http://okyopharma.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "CLN Interest settled in shares, shares", "documentation": "Number of shares issued CLN interest settled in shares." } } }, "auth_ref": [] }, "OKYO_NumberOfSharesIssuedCLNSettledInShares": { "xbrltype": "sharesItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "NumberOfSharesIssuedCLNSettledInShares", "presentation": [ "http://okyopharma.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "CLN settled in Shares, shares", "documentation": "Number of shares issued CLN settled in shares." } } }, "auth_ref": [] }, "OKYO_NumberOfSharesIssuedForConvertibleLoanNoteAndInterestSettlement": { "xbrltype": "sharesItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "NumberOfSharesIssuedForConvertibleLoanNoteAndInterestSettlement", "presentation": [ "http://okyopharma.com/role/ScheduleOfAuthorizedIssueUnlimitedNumberOfParValueSharesDetails" ], "lang": { "en-us": { "role": { "label": "Convertible loan note and interest settled in shares", "documentation": "Number of shares issued for convertible loan note and interest settlement." } } }, "auth_ref": [] }, "OKYO_NumberOfSharesIssuedOfFundraisingNet": { "xbrltype": "sharesItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "NumberOfSharesIssuedOfFundraisingNet", "presentation": [ "http://okyopharma.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares issued for Fundraising, net, shares", "documentation": "Number of shares issued of fundraising net." } } }, "auth_ref": [] }, "OKYO_NumberOfSharesIssuedOnExpensesSettledInShares": { "xbrltype": "sharesItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "NumberOfSharesIssuedOnExpensesSettledInShares", "presentation": [ "http://okyopharma.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Expenses settled in shares, shares", "documentation": "Expenses settled in shares, shares." } } }, "auth_ref": [] }, "ifrs-full_NumberOfSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfSharesOutstanding", "presentation": [ "http://okyopharma.com/role/ScheduleOfAuthorizedIssueUnlimitedNumberOfParValueSharesDetails", "http://okyopharma.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance, shares", "periodEndLabel": "Balance, shares", "label": "Number of shares outstanding" } }, "en": { "role": { "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]" } } }, "auth_ref": [ "r102", "r139", "r161" ] }, "OKYO_OctoberThreeTwoThousandTwentyFourMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "OctoberThreeTwoThousandTwentyFourMember", "presentation": [ "http://okyopharma.com/role/ScheduleOfShareOptionsOutstandingExpiryDatesAndExercisePricesDetails" ], "lang": { "en-us": { "role": { "label": "October 3, 2024 [member]", "documentation": "October 3, 2024 [member]" } } }, "auth_ref": [] }, "OKYO_OctoberTwentyTwoThousandTwentyThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "OctoberTwentyTwoThousandTwentyThreeMember", "presentation": [ "http://okyopharma.com/role/ScheduleOfShareOptionsOutstandingExpiryDatesAndExercisePricesDetails" ], "lang": { "en-us": { "role": { "label": "October 20, 2023 [member]", "documentation": "October 20, 2023 [member]" } } }, "auth_ref": [] }, "ifrs-full_OperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OperatingExpense", "crdr": "debit", "calculation": { "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "ifrs-full_OperatingExpenseExcludingCostOfSales", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "negatedLabel": "Operating Expenses", "label": "Operating expense" } } }, "auth_ref": [ "r347" ] }, "ifrs-full_OperatingExpenseExcludingCostOfSales": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OperatingExpenseExcludingCostOfSales", "crdr": "debit", "calculation": { "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total operating expenses", "label": "Operating expense excluding cost of sales" } } }, "auth_ref": [ "r347" ] }, "OKYO_OptionLifePeriod": { "xbrltype": "durationItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "OptionLifePeriod", "presentation": [ "http://okyopharma.com/role/ScheduleOfShareBasedPaymentAwardModelInputsOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Option life", "documentation": "Options life period." } } }, "auth_ref": [] }, "ifrs-full_OtherComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeAbstract", "presentation": [ "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive loss:" } } }, "auth_ref": [] }, "ifrs-full_OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation", "crdr": "credit", "calculation": { "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Exchange differences on translating foreign operations" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, before tax, after reclassification adjustments, related to exchange differences on translation of financial statements of foreign operations. [Refer: Other comprehensive income, before tax]" } } }, "auth_ref": [ "r157", "r169" ] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation", "crdr": "credit", "presentation": [ "http://okyopharma.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Currency translation" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r157", "r168" ] }, "OKYO_OtherIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "OtherIncomeExpenseAbstract", "presentation": [ "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Other income/(expense):", "documentation": "Other income expense abstract." } } }, "auth_ref": [] }, "ifrs-full_OtherPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherPayables", "crdr": "credit", "calculation": { "http://okyopharma.com/role/ScheduleOfTradeAndOtherPayablesDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentPayables", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://okyopharma.com/role/ScheduleOfTradeAndOtherPayablesDetails" ], "lang": { "en-us": { "role": { "label": "Other payables" } }, "en": { "role": { "documentation": "Amounts payable that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r343" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r283" ] }, "ifrs-full_OtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherReceivables", "crdr": "debit", "calculation": { "http://okyopharma.com/role/ScheduleOfPrepaidExpensesAndOtherReceivablesDetails": { "parentTag": "ifrs-full_TradeAndOtherReceivables", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://okyopharma.com/role/ScheduleOfPrepaidExpensesAndOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other receivables", "label": "Other receivables [Default Label]" } }, "en": { "role": { "documentation": "The amount receivable by the entity that it does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r209", "r215" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r231" ] }, "ifrs-full_OtherReservesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherReservesMember", "presentation": [ "http://okyopharma.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Other reserves [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]" } } }, "auth_ref": [ "r104", "r147" ] }, "ifrs-full_OtherShorttermEmployeeBenefits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherShorttermEmployeeBenefits", "crdr": "debit", "presentation": [ "http://okyopharma.com/role/ScheduleOfEmployeesCostAndNumberOfEmployeesExplanatoryDetails" ], "lang": { "en-us": { "role": { "label": "Recruitment costs" } } }, "auth_ref": [ "r332" ] }, "OKYO_OtherkeymanagementpersonnelMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "OtherkeymanagementpersonnelMember", "presentation": [ "http://okyopharma.com/role/ScheduleOfShareOptionsGrantedToDirectorsDetails" ], "lang": { "en-us": { "role": { "label": "Other keymanagement personnel [member]", "documentation": "Other keymanagement personnel [member]" } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r247", "r258", "r272", "r298" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Amount" } } }, "auth_ref": [ "r250", "r261", "r275", "r301" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r250", "r261", "r275", "r301" ] }, "OKYO_PKFLittlejohnLLPMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "PKFLittlejohnLLPMember", "presentation": [ "http://okyopharma.com/role/ScheduleOfCompanyAuditorsFeesDetails" ], "lang": { "en-us": { "role": { "label": "PKF Littlejohn LLP [member]", "documentation": "PKF Littlejohn LLP [member]" } } }, "auth_ref": [] }, "ifrs-full_ParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ParValuePerShare", "presentation": [ "http://okyopharma.com/role/ConvertibleLoanInstrumentsDetailsNarrative", "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Noteholder price, per share" } }, "en": { "role": { "documentation": "The nominal value per share." } } }, "auth_ref": [ "r101", "r138", "r160" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PayVsPerformanceDisclosureLineItems", "auth_ref": [ "r279" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r282" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r282" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r281" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name" } } }, "auth_ref": [ "r284" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r280" ] }, "OKYO_PhaseIHumanClinicalTrialMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "PhaseIHumanClinicalTrialMember", "presentation": [ "http://okyopharma.com/role/ScheduleOfMilestonesPaymentDetails" ], "lang": { "en-us": { "role": { "label": "Phase I Human Clinical Trial [member]", "documentation": "Phase I Human Clinical Trial [member]" } } }, "auth_ref": [] }, "OKYO_PhaseIIHumanClinicalTrialMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "PhaseIIHumanClinicalTrialMember", "presentation": [ "http://okyopharma.com/role/ScheduleOfMilestonesPaymentDetails" ], "lang": { "en-us": { "role": { "label": "Phase II Human Clinical Trial [member]", "documentation": "Phase II Human Clinical Trial [member]" } } }, "auth_ref": [] }, "OKYO_PhaseIIIHumanClinicalTrialMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "PhaseIIIHumanClinicalTrialMember", "presentation": [ "http://okyopharma.com/role/ScheduleOfMilestonesPaymentDetails" ], "lang": { "en-us": { "role": { "label": "Phase III Human Clinical Trial [member]", "documentation": "Phase III Human Clinical Trial [member]" } } }, "auth_ref": [] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r281" ] }, "OKYO_PostEmploymentBenefitsMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "PostEmploymentBenefitsMember", "presentation": [ "http://okyopharma.com/role/ScheduleOfKeyManagementPersonnelCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Post employment benefits [member]", "documentation": "Post employment benefits [member]" } } }, "auth_ref": [] }, "ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PostemploymentBenefitExpenseDefinedContributionPlans", "crdr": "debit", "presentation": [ "http://okyopharma.com/role/RemunerationOfKeyManagementPersonnelDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Pension contribution" } } }, "auth_ref": [ "r13", "r116" ] }, "OKYO_PostemploymentSeverancePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "PostemploymentSeverancePayments", "crdr": "debit", "presentation": [ "http://okyopharma.com/role/RemunerationOfKeyManagementPersonnelDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Post-employment severance payments", "documentation": "Post-employment severance payments." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r225" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PreCommencementTenderOffer", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r227" ] }, "ifrs-full_Prepayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Prepayments", "crdr": "debit", "calculation": { "http://okyopharma.com/role/ScheduleOfPrepaidExpensesAndOtherReceivablesDetails": { "parentTag": "ifrs-full_TradeAndOtherReceivables", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://okyopharma.com/role/ScheduleOfPrepaidExpensesAndOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Prepayments" } }, "en": { "role": { "documentation": "Receivables that represent amounts paid for goods and services before they have been delivered." } } }, "auth_ref": [ "r209", "r215" ] }, "OKYO_ProceedsFromConvertibleLoanNote": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "ProceedsFromConvertibleLoanNote", "crdr": "debit", "calculation": { "http://okyopharma.com/role/StatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://okyopharma.com/role/StatementsOfCashFlows", "http://okyopharma.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Proceeds from Convertible loan note", "verboseLabel": "Proceeds from convertible loan note", "documentation": "Proceeds from convertible loan note." } } }, "auth_ref": [] }, "OKYO_ProceedsFromFundraisingNetAndIssuanceOfOrdinaryShares": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "ProceedsFromFundraisingNetAndIssuanceOfOrdinaryShares", "crdr": "debit", "calculation": { "http://okyopharma.com/role/StatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://okyopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from fundraising, net and issuance of ordinary shares", "documentation": "Proceeds from fundraising net and issuance of ordinary shares." } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities", "crdr": "debit", "presentation": [ "http://okyopharma.com/role/AccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds from sales of intangible assets, classified as investing activities" } }, "en": { "role": { "documentation": "The cash inflow from sales of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r180" ] }, "ifrs-full_ProductsAndServicesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProductsAndServicesAxis", "presentation": [ "http://okyopharma.com/role/ScheduleOfMilestonesPaymentDetails" ], "lang": { "en-us": { "role": { "label": "Products and services [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r89", "r185", "r199" ] }, "ifrs-full_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProductsAndServicesDomain", "presentation": [ "http://okyopharma.com/role/ScheduleOfMilestonesPaymentDetails" ], "lang": { "en": { "role": { "documentation": "This member stands for the entity's products and services. It also represents the standard value for the 'Products and services' axis if no other member is used." } } }, "auth_ref": [ "r89", "r185", "r199" ] }, "ifrs-full_ProfessionalFeesExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfessionalFeesExpense", "crdr": "debit", "presentation": [ "http://okyopharma.com/role/ScheduleOfOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Legal and Professional fees" } } }, "auth_ref": [ "r341" ] }, "ifrs-full_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://okyopharma.com/role/AccountingPoliciesDetailsNarrative", "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss", "http://okyopharma.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Loss for the year", "label": "Loss for the period", "negatedLabel": "Net loss" } }, "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r37", "r40", "r84", "r85", "r122", "r127", "r146", "r164", "r182", "r188" ] }, "ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity", "crdr": "credit", "presentation": [ "http://okyopharma.com/role/SummaryOfIncomeAndShareDataUsedInBasicAndDilutedLossPerShareComputationsDetails" ], "lang": { "en-us": { "role": { "label": "(Loss) attributable to equity holders of the company" } }, "en": { "role": { "documentation": "The profit (loss) attributable to ordinary equity holders of the parent entity. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r23" ] }, "ifrs-full_ProfitLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossBeforeTax", "crdr": "credit", "calculation": { "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 1.0 }, "http://okyopharma.com/role/StatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://okyopharma.com/role/StatementsOfCashFlows", "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations before income taxes", "label": "Loss from operations before income taxes" } } }, "auth_ref": [ "r75", "r197", "r198", "r211", "r212" ] }, "ifrs-full_PropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://okyopharma.com/role/BalanceSheets": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://okyopharma.com/role/BalanceSheets", "http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentDetails", "http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentLocatedInOperatingSegmentDetails" ], "lang": { "en-us": { "role": { "label": "Property and Equipment, net", "verboseLabel": "Net book value", "terseLabel": "Total" } }, "en": { "role": { "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r9", "r114", "r148" ] }, "OKYO_PropertyPlantAndEquipmentCost": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "PropertyPlantAndEquipmentCost", "crdr": "debit", "presentation": [ "http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Property and equipment, cost, balance", "periodEndLabel": "Property and equipment, cost, balance", "documentation": "Property and equipment, cost.", "label": "PropertyPlantAndEquipmentCost" } } }, "auth_ref": [] }, "OKYO_PropertyPlantAndEquipmentDepreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "PropertyPlantAndEquipmentDepreciation", "crdr": "credit", "presentation": [ "http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Depreciation, beginning balance", "periodEndLabel": "Depreciation, ending balance", "documentation": "Property plant and equipment depreciation.", "label": "PropertyPlantAndEquipmentDepreciation" } } }, "auth_ref": [] }, "ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod", "crdr": "credit", "calculation": { "http://okyopharma.com/role/StatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://okyopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Short Term Investments", "label": "Purchase of investments other than investments accounted for using equity method" } }, "en": { "role": { "documentation": "The cash outflow for the purchase of investments other than investments accounted for using equity method. [Refer: Investments accounted for using equity method; Investments other than investments accounted for using equity method]" } } }, "auth_ref": [ "r333" ] }, "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://okyopharma.com/role/StatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://okyopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Acquisition of property, plant and equipment", "label": "Purchase of property, plant and equipment, classified as investing activities" } }, "en": { "role": { "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r179" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r279" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r279" ] }, "ifrs-full_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RangeAxis", "presentation": [ "http://okyopharma.com/role/ScheduleOfShareBasedPaymentAwardModelInputsOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Range [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r33", "r52", "r62", "r71", "r106", "r183", "r184", "r338" ] }, "ifrs-full_RangeDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RangeDomain", "presentation": [ "http://okyopharma.com/role/ScheduleOfShareBasedPaymentAwardModelInputsOptionsGrantedDetails" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } } }, "auth_ref": [ "r33", "r52", "r62", "r71", "r106", "r183", "r184", "r338" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RecoveryOfErrCompDisclosureLineItems", "auth_ref": [ "r242", "r253", "r267", "r293" ] }, "ifrs-full_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "ifrs-full_OperatingExpenseExcludingCostOfSales", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "negatedLabel": "Research and development", "label": "Research and development expense" } } }, "auth_ref": [ "r27", "r125" ] }, "OKYO_ResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "ResearchAndDevelopmentMember", "presentation": [ "http://okyopharma.com/role/ScheduleOfEmployeesCostAndNumberOfEmployeesExplanatoryDetails" ], "lang": { "en-us": { "role": { "label": "Research and development [member]", "documentation": "Research and development [member]" } } }, "auth_ref": [] }, "OKYO_ResearchAndDevelopmentTaxClaim": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "ResearchAndDevelopmentTaxClaim", "crdr": "debit", "presentation": [ "http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetails" ], "lang": { "en-us": { "role": { "label": "Difference in tax rates", "documentation": "Research and Development tax claim." } } }, "auth_ref": [] }, "ifrs-full_ReserveOfSharebasedPayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReserveOfSharebasedPayments", "crdr": "credit", "calculation": { "http://okyopharma.com/role/BalanceSheets": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://okyopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Share options reserve" } }, "en": { "role": { "documentation": "A component of equity resulting from share-based payments." } } }, "auth_ref": [ "r345" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r243", "r254", "r268", "r294" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date" } } }, "auth_ref": [ "r244", "r255", "r269", "r295" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement does not require Recovery" } } }, "auth_ref": [ "r251", "r262", "r276", "r302" ] }, "ifrs-full_RetainedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetainedEarnings", "crdr": "credit", "calculation": { "http://okyopharma.com/role/BalanceSheets": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://okyopharma.com/role/AccountingPoliciesDetailsNarrative", "http://okyopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Retained deficit", "negatedLabel": "Accumulated deficit" } }, "en": { "role": { "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r210", "r216", "r217" ] }, "ifrs-full_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetainedEarningsMember", "presentation": [ "http://okyopharma.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Retained earnings [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r147", "r213" ] }, "ifrs-full_RevenueFromInterest": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RevenueFromInterest", "crdr": "credit", "calculation": { "http://okyopharma.com/role/ScheduleOfFinanceIncomeAndCostsDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://okyopharma.com/role/ScheduleOfFinanceIncomeAndCostsDetails" ], "lang": { "en-us": { "role": { "label": "Interest income" } }, "en": { "role": { "documentation": "The amount of income arising from interest." } } }, "auth_ref": [ "r47", "r81", "r88", "r341" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r311" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r311" ] }, "OKYO_ScheduleOfCompanyAuditorsFeesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "ScheduleOfCompanyAuditorsFeesAbstract", "auth_ref": [] }, "OKYO_ScheduleOfCompanyAuditorsFeesTable": { "xbrltype": "stringItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "ScheduleOfCompanyAuditorsFeesTable", "presentation": [ "http://okyopharma.com/role/ScheduleOfCompanyAuditorsFeesDetails" ], "lang": { "en-us": { "role": { "label": "ScheduleOfCompanyAuditorsFeesTable [Table]" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12bTitle", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r219" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12gTitle", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r223" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SecurityExchangeName", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r222" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SecurityReportingObligation", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r228" ] }, "OKYO_ServiceAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "ServiceAgreementMember", "presentation": [ "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Service agreement [member]", "documentation": "Service agreement [member]" } } }, "auth_ref": [] }, "ifrs-full_ServicesReceivedRelatedPartyTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ServicesReceivedRelatedPartyTransactions", "crdr": "debit", "presentation": [ "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Service received related party transaction" } }, "en": { "role": { "documentation": "The amount of services received in related party transactions. [Refer: Total for all related parties [member]]" } } }, "auth_ref": [ "r177", "r206" ] }, "ifrs-full_SettlementOfLiabilitiesOnBehalfOfEntityByRelatedPartyRelatedPartyTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SettlementOfLiabilitiesOnBehalfOfEntityByRelatedPartyRelatedPartyTransactions", "presentation": [ "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Settlement of liabilities on behalf of entity by related party transactions" } }, "en": { "role": { "documentation": "The amount of liabilities settled on behalf of the entity by a related party in related party transactions. [Refer: Total for all related parties [member]]" } } }, "auth_ref": [ "r178", "r207" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "auth_ref": [] }, "OKYO_ShareBasedPaymentCharge": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "ShareBasedPaymentCharge", "crdr": "debit", "presentation": [ "http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share based payment charge", "documentation": "Share based payment charge." } } }, "auth_ref": [] }, "OKYO_ShareBasedPaymentChargeForfeiture": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "ShareBasedPaymentChargeForfeiture", "crdr": "debit", "presentation": [ "http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share based payment charge forfeiture", "documentation": "Share based payment charge forfeiture." } } }, "auth_ref": [] }, "ifrs-full_SharePremium": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SharePremium", "crdr": "credit", "calculation": { "http://okyopharma.com/role/BalanceSheets": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://okyopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Share premium" } }, "en": { "role": { "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r210", "r216" ] }, "OKYO_SharesIssuedInLieuOfBonus": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "SharesIssuedInLieuOfBonus", "crdr": "debit", "calculation": { "http://okyopharma.com/role/StatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://okyopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Shares Issued in lieu of bonus", "documentation": "Shares issued in lieu of bonus." } } }, "auth_ref": [] }, "OKYO_SharesIssuedInLieuOfConsultancyFees": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "SharesIssuedInLieuOfConsultancyFees", "crdr": "debit", "calculation": { "http://okyopharma.com/role/StatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://okyopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Shares Issued in lieu of consultancy fees", "documentation": "Shares issued in lieu of consultancy fees." } } }, "auth_ref": [] }, "OKYO_SharesIssuedInLieuOfInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "SharesIssuedInLieuOfInterest", "crdr": "debit", "calculation": { "http://okyopharma.com/role/StatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://okyopharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Shares Issued in lieu of interest", "documentation": "Shares issued in lieu of interest." } } }, "auth_ref": [] }, "OKYO_SharesIssuedOnConvertibleDebtConversionShares": { "xbrltype": "sharesItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "SharesIssuedOnConvertibleDebtConversionShares", "presentation": [ "http://okyopharma.com/role/ConvertibleLoanInstrumentsDetailsNarrative", "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of shares issued for debt conversion", "verboseLabel": "Convertible loan note conversion", "documentation": "Shares issued on convertible debt conversion, shares." } } }, "auth_ref": [] }, "OKYO_SharesIssuedOnOptionsCharge": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "SharesIssuedOnOptionsCharge", "crdr": "credit", "presentation": [ "http://okyopharma.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Options charge", "documentation": "Shares issued on options charge" } } }, "auth_ref": [] }, "OKYO_SharesIssuedOnTotalTransactions": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "SharesIssuedOnTotalTransactions", "crdr": "credit", "presentation": [ "http://okyopharma.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Total transactions", "documentation": "Shares issued on total transactions" } } }, "auth_ref": [] }, "OKYO_SharesIssuedOnTotalTransactionsShares": { "xbrltype": "sharesItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "SharesIssuedOnTotalTransactionsShares", "presentation": [ "http://okyopharma.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Total transactions, shares", "documentation": "Shares issued on total transactions shares," } } }, "auth_ref": [] }, "OKYO_SharesIssuedShareOfRealtedPartyLoanConversion": { "xbrltype": "sharesItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "SharesIssuedShareOfRealtedPartyLoanConversion", "presentation": [ "http://okyopharma.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Issuance of shares, related party loan conversion, shares", "documentation": "Shares issued share of realted party loan conversion" } } }, "auth_ref": [] }, "OKYO_SharesIssuedSharesOnFeesOnCLNIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "SharesIssuedSharesOnFeesOnCLNIssuance", "presentation": [ "http://okyopharma.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Fees on CLN issuance, shares", "documentation": "Shares issued shares on fees on CLN issuance." } } }, "auth_ref": [] }, "OKYO_SharesIssuedSharesOnlieuOfBonus": { "xbrltype": "sharesItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "SharesIssuedSharesOnlieuOfBonus", "presentation": [ "http://okyopharma.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares issued in lieu of Bonus, shares", "documentation": "Shares issued shares on lieu of bonus." } } }, "auth_ref": [] }, "OKYO_SharesIssuedSharesOnlieuOfConsultancyFees": { "xbrltype": "sharesItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "SharesIssuedSharesOnlieuOfConsultancyFees", "presentation": [ "http://okyopharma.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares issued in lieu of consultancy fees, shares", "documentation": "Shares issued shares on lieu of consultancy fees." } } }, "auth_ref": [] }, "OKYO_SharesIssuedSharesOnlieuOfInterest": { "xbrltype": "sharesItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "SharesIssuedSharesOnlieuOfInterest", "presentation": [ "http://okyopharma.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares issued in lieu of interest, shares", "documentation": "Shares issued shares on lieu of interest." } } }, "auth_ref": [] }, "OKYO_SharesIssuedValueOfFundraisingNet": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "SharesIssuedValueOfFundraisingNet", "crdr": "credit", "presentation": [ "http://okyopharma.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares issued for Fundraising, net", "documentation": "Issuance of shares fundraising net." } } }, "auth_ref": [] }, "OKYO_SharesIssuedValueOfRealtedPartyLoanConversion": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "SharesIssuedValueOfRealtedPartyLoanConversion", "crdr": "credit", "presentation": [ "http://okyopharma.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Issuance of shares, related party loan conversion", "documentation": "Shares issued value of realted party loan conversion" } } }, "auth_ref": [] }, "OKYO_SharesIssuedValueOnExpensesSettledInShares": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "SharesIssuedValueOnExpensesSettledInShares", "crdr": "credit", "presentation": [ "http://okyopharma.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Expenses settled in shares", "documentation": "Expenses settled in shares." } } }, "auth_ref": [] }, "OKYO_SharesIssuedValueOnFeesOnCLNIssuance": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "SharesIssuedValueOnFeesOnCLNIssuance", "crdr": "credit", "presentation": [ "http://okyopharma.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Fees on CLN issuance", "documentation": "Shares issued value on fees on CLN issuance." } } }, "auth_ref": [] }, "OKYO_SharesIssuedValueOnlieuOfBonus": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "SharesIssuedValueOnlieuOfBonus", "crdr": "credit", "presentation": [ "http://okyopharma.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares issued in lieu of Bonus", "documentation": "Shares issued value on lieu of bonus." } } }, "auth_ref": [] }, "OKYO_SharesIssuedValueOnlieuOfConsultancyFees": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "SharesIssuedValueOnlieuOfConsultancyFees", "crdr": "credit", "presentation": [ "http://okyopharma.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares issued in lieu of consultancy fees", "documentation": "Shares issued value on lieu of consultancy fees." } } }, "auth_ref": [] }, "OKYO_SharesIssuedValueOnlieuOfInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "SharesIssuedValueOnlieuOfInterest", "crdr": "credit", "presentation": [ "http://okyopharma.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares issued in lieu of interest", "documentation": "Shares issued value on lieu of interest." } } }, "auth_ref": [] }, "ifrs-full_ShorttermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShorttermBorrowings", "crdr": "credit", "presentation": [ "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Borrowings" } }, "en": { "role": { "documentation": "The amount of current borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r343" ] }, "OKYO_ShorttermCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "ShorttermCreditFacilityMember", "presentation": [ "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shortterm credit facility [member]", "documentation": "Shortterm credit facility [member]" } } }, "auth_ref": [] }, "ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShorttermDepositsClassifiedAsCashEquivalents", "crdr": "debit", "presentation": [ "http://okyopharma.com/role/ScheduleOfShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Cash deposits" } }, "en": { "role": { "documentation": "A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]" } } }, "auth_ref": [ "r336" ] }, "ifrs-full_ShorttermEmployeeBenefitsAccruals": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShorttermEmployeeBenefitsAccruals", "crdr": "credit", "calculation": { "http://okyopharma.com/role/ScheduleOfTradeAndOtherPayablesDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentPayables", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://okyopharma.com/role/ScheduleOfTradeAndOtherPayablesDetails" ], "lang": { "en-us": { "role": { "label": "Bonus accrual" } }, "en": { "role": { "documentation": "The amount of accruals for employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services. [Refer: Accruals classified as current]" } } }, "auth_ref": [ "r346" ] }, "ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShorttermInvestmentsClassifiedAsCashEquivalents", "crdr": "debit", "calculation": { "http://okyopharma.com/role/BalanceSheets": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://okyopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Short Term Investments" } }, "en": { "role": { "documentation": "A classification of cash equivalents representing short-term investments. [Refer: Cash equivalents]" } } }, "auth_ref": [ "r336" ] }, "ifrs-full_SocialSecurityContributions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SocialSecurityContributions", "crdr": "debit", "presentation": [ "http://okyopharma.com/role/ScheduleOfEmployeesCostAndNumberOfEmployeesExplanatoryDetails" ], "lang": { "en-us": { "role": { "label": "Social security costs" } } }, "auth_ref": [ "r332" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SolicitingMaterial", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r226" ] }, "ifrs-full_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of cash flows [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityAbstract", "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityTable", "presentation": [ "http://okyopharma.com/role/ScheduleOfAuthorizedIssueUnlimitedNumberOfParValueSharesDetails", "http://okyopharma.com/role/ScheduleOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails", "http://okyopharma.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement of changes in equity [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } } }, "auth_ref": [ "r147" ] }, "ifrs-full_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of financial position [abstract]" } } }, "auth_ref": [] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r246", "r257", "r271", "r297" ] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List, Table" } } }, "auth_ref": [ "r290" ] }, "ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense", "crdr": "credit", "presentation": [ "http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetails" ], "lang": { "en-us": { "role": { "label": "Tax losses arising in the year not recognized" } } }, "auth_ref": [ "r174", "r205" ] }, "ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss", "crdr": "debit", "presentation": [ "http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetails" ], "lang": { "en-us": { "role": { "label": "Expenses not deductible for taxation" } }, "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to expenses not deductible in determining taxable profit (tax loss). [Refer: Accounting profit]" } } }, "auth_ref": [ "r2", "r109" ] }, "ifrs-full_TaxEffectOfTaxLosses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TaxEffectOfTaxLosses", "crdr": "debit", "presentation": [ "http://okyopharma.com/role/TaxationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Tax effect of tax losses" } }, "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to tax losses. [Refer: Accounting profit]" } } }, "auth_ref": [ "r2", "r109" ] }, "OKYO_TaxIncreaseFromEffectOfCapitalAllowancesAndDepreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "TaxIncreaseFromEffectOfCapitalAllowancesAndDepreciation", "crdr": "debit", "presentation": [ "http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetails" ], "lang": { "en-us": { "role": { "label": "Tax increase from effect of capital allowances and depreciation", "documentation": "Tax increase from effect of capital allowances and depreciation." } } }, "auth_ref": [] }, "OKYO_ThreeToTwelveMonthsMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "ThreeToTwelveMonthsMember", "presentation": [ "http://okyopharma.com/role/SummaryOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "3 to 12 months [member]", "documentation": "3 to 12 months [member]" } } }, "auth_ref": [] }, "OKYO_TizianaLifeSciencesLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "TizianaLifeSciencesLtdMember", "presentation": [ "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Tiziana Life Sciences Ltd. [member]", "documentation": "Tiziana Life Sciences Ltd. [member]" } } }, "auth_ref": [] }, "ifrs-full_TopOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TopOfRangeMember", "presentation": [ "http://okyopharma.com/role/ScheduleOfShareBasedPaymentAwardModelInputsOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Top of range [member]" } }, "en": { "role": { "documentation": "This member stands for top of a range." } } }, "auth_ref": [ "r33", "r52", "r62", "r71", "r106", "r183", "r184", "r338" ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r282" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r289" ] }, "ifrs-full_TradeAndOtherCurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentPayables", "crdr": "credit", "calculation": { "http://okyopharma.com/role/BalanceSheets": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 1.0 }, "http://okyopharma.com/role/ScheduleOfTradeAndOtherPayablesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://okyopharma.com/role/BalanceSheets", "http://okyopharma.com/role/ScheduleOfTradeAndOtherPayablesDetails" ], "lang": { "en-us": { "role": { "label": "Trade and other payables", "totalLabel": "Trade and other payables" } }, "en": { "role": { "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]" } } }, "auth_ref": [ "r151" ] }, "ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentPayablesToRelatedParties", "crdr": "credit", "calculation": { "http://okyopharma.com/role/BalanceSheets": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://okyopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Related party payable" } }, "en": { "role": { "documentation": "The amount of current payables due to related parties. [Refer: Total for all related parties [member]; Payables to related parties]" } } }, "auth_ref": [ "r346" ] }, "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers", "crdr": "credit", "calculation": { "http://okyopharma.com/role/ScheduleOfTradeAndOtherPayablesDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentPayables", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://okyopharma.com/role/ScheduleOfTradeAndOtherPayablesDetails" ], "lang": { "en-us": { "role": { "label": "Trade payables" } }, "en": { "role": { "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]" } } }, "auth_ref": [ "r214", "r346" ] }, "ifrs-full_TradeAndOtherPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherPayables", "crdr": "credit", "calculation": { "http://okyopharma.com/role/SummaryOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails": { "parentTag": "ifrs-full_FinancialLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://okyopharma.com/role/SummaryOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Trade and other payables", "label": "Trade and other payables [Default Label]" } }, "en": { "role": { "documentation": "The amount of trade payables and other payables. [Refer: Trade payables; Other payables]" } } }, "auth_ref": [ "r151" ] }, "ifrs-full_TradeAndOtherPayablesToRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherPayablesToRelatedParties", "crdr": "credit", "calculation": { "http://okyopharma.com/role/SummaryOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails": { "parentTag": "ifrs-full_FinancialLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://okyopharma.com/role/SummaryOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Related party payables" } }, "en": { "role": { "documentation": "The amount of payables due to related parties. [Refer: Total for all related parties [member]]" } } }, "auth_ref": [ "r346" ] }, "ifrs-full_TradeAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherReceivables", "crdr": "debit", "calculation": { "http://okyopharma.com/role/BalanceSheets": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 4.0 }, "http://okyopharma.com/role/ScheduleOfPrepaidExpensesAndOtherReceivablesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://okyopharma.com/role/BalanceSheets", "http://okyopharma.com/role/ScheduleOfPrepaidExpensesAndOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Other receivables", "totalLabel": "Prepaid expenses and other receivables" } }, "en": { "role": { "documentation": "The amount of trade receivables and other receivables. [Refer: Trade receivables; Other receivables]" } } }, "auth_ref": [ "r142", "r149", "r158" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r310" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r312" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "TradingSymbol", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "OKYO_TranslationReserveMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "TranslationReserveMember", "presentation": [ "http://okyopharma.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Translation reserve [member]", "documentation": "Translation reserve [member]" } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Adoption Date" } } }, "auth_ref": [ "r313" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Arrangement Duration" } } }, "auth_ref": [ "r314" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Expiration Date" } } }, "auth_ref": [ "r314" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r312" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Title" } } }, "auth_ref": [ "r312" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Termination Date" } } }, "auth_ref": [ "r313" ] }, "ifrs-full_TypesOfContractsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfContractsAxis", "presentation": [ "http://okyopharma.com/role/ConvertibleLoanInstrumentsDetailsNarrative", "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Types of contracts [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r187", "r189", "r201" ] }, "ifrs-full_TypesOfContractsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfContractsDomain", "presentation": [ "http://okyopharma.com/role/ConvertibleLoanInstrumentsDetailsNarrative", "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en": { "role": { "documentation": "This member stands for all types of contracts with customers. It also represents the standard value for the 'Types of contracts' axis if no other member is used." } } }, "auth_ref": [ "r187", "r189", "r201" ] }, "OKYO_UKMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "UKMember", "presentation": [ "http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentLocatedInOperatingSegmentDetails" ], "lang": { "en-us": { "role": { "label": "UK [member]", "documentation": "UK [member]" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r309" ] }, "OKYO_UnitedStateMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "UnitedStateMember", "presentation": [ "http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentLocatedInOperatingSegmentDetails" ], "lang": { "en-us": { "role": { "label": "US [member]", "documentation": "US [member]" } } }, "auth_ref": [] }, "OKYO_UnitedStatesDollarMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "UnitedStatesDollarMember", "presentation": [ "http://okyopharma.com/role/ScheduleOfCashAndCashEquivalentDetails", "http://okyopharma.com/role/ScheduleOfShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "USD [member]", "documentation": "USD [member]" } } }, "auth_ref": [] }, "OKYO_UnsecuredLoanAgreementFourMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "UnsecuredLoanAgreementFourMember", "presentation": [ "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unsecured loan agreement four [member]", "documentation": "Unsecured loan agreement four [member]" } } }, "auth_ref": [] }, "OKYO_UnsecuredLoanAgreementOneMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "UnsecuredLoanAgreementOneMember", "presentation": [ "http://okyopharma.com/role/ConvertibleLoanInstrumentsDetailsNarrative", "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unsecured loan agreement one [member]", "documentation": "Unsecured loan agreement one [member]" } } }, "auth_ref": [] }, "OKYO_UnsecuredLoanAgreementThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "UnsecuredLoanAgreementThreeMember", "presentation": [ "http://okyopharma.com/role/ConvertibleLoanInstrumentsDetailsNarrative", "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unsecured loan agreement three [member]", "documentation": "Unsecured loan agreement three [member]" } } }, "auth_ref": [] }, "OKYO_UnsecuredLoanAgreementTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "UnsecuredLoanAgreementTwoMember", "presentation": [ "http://okyopharma.com/role/ConvertibleLoanInstrumentsDetailsNarrative", "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unsecured loan agreement two [member]", "documentation": "Unsecured loan agreement two [member]" } } }, "auth_ref": [] }, "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment": { "xbrltype": "durationItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "presentation": [ "http://okyopharma.com/role/DisclosureOfEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "label": "Estimated useful lives" } }, "en": { "role": { "documentation": "The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r5", "r111" ] }, "ifrs-full_ValueAddedTaxReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ValueAddedTaxReceivables", "crdr": "debit", "calculation": { "http://okyopharma.com/role/ScheduleOfPrepaidExpensesAndOtherReceivablesDetails": { "parentTag": "ifrs-full_TradeAndOtherReceivables", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://okyopharma.com/role/ScheduleOfPrepaidExpensesAndOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "VAT receivable" } }, "en": { "role": { "documentation": "The amount of receivables related to a value added tax." } } }, "auth_ref": [ "r344" ] }, "OKYO_ValueOfSharesIssuedForConvertibleLoanNoteAndInterestSettlement": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "ValueOfSharesIssuedForConvertibleLoanNoteAndInterestSettlement", "crdr": "credit", "presentation": [ "http://okyopharma.com/role/ScheduleOfAuthorizedIssueUnlimitedNumberOfParValueSharesDetails" ], "lang": { "en-us": { "role": { "label": "Convertible loan note and interest settled in shares, value", "documentation": "Value of shares issued for convertible loan note and interest settlement." } } }, "auth_ref": [] }, "OKYO_VestingPeriodsDescription": { "xbrltype": "stringItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "VestingPeriodsDescription", "presentation": [ "http://okyopharma.com/role/ScheduleOfShareBasedPaymentAwardModelInputsOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Vesting periods", "documentation": "Vesting period description." } } }, "auth_ref": [] }, "ifrs-full_WagesAndSalaries": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WagesAndSalaries", "crdr": "debit", "presentation": [ "http://okyopharma.com/role/ScheduleOfEmployeesCostAndNumberOfEmployeesExplanatoryDetails" ], "lang": { "en-us": { "role": { "label": "Wages and salaries" } } }, "auth_ref": [ "r332" ] }, "OKYO_WarrantReceived": { "xbrltype": "sharesItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "WarrantReceived", "presentation": [ "http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrant received", "documentation": "Warrant received." } } }, "auth_ref": [] }, "ifrs-full_WarrantReserve": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WarrantReserve", "crdr": "credit", "calculation": { "http://okyopharma.com/role/BalanceSheets": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://okyopharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Warrants reserve" } }, "en": { "role": { "documentation": "A component of equity resulting from issuing share purchase warrants, other than those resulting from share-based payment arrangements. [Refer: Reserve of share-based payments]" } } }, "auth_ref": [ "r345" ] }, "ifrs-full_WarrantReserveMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WarrantReserveMember", "presentation": [ "http://okyopharma.com/role/ScheduleOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails", "http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrant reserve [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity resulting from issuing share purchase warrants, other than those resulting from share-based payment arrangements. [Refer: Reserve of share-based payments [member]]" } } }, "auth_ref": [ "r340" ] }, "OKYO_WarrantReservesMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "WarrantReservesMember", "presentation": [ "http://okyopharma.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Warrant reserves [member]", "documentation": "Warrant reserves [member]" } } }, "auth_ref": [] }, "OKYO_WarrantsExercisablePricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "WarrantsExercisablePricePerShare", "presentation": [ "http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants exercisable price", "documentation": "Warrants exercisable price per share." } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019", "presentation": [ "http://okyopharma.com/role/ScheduleOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Weighted average exercise price, exercisable", "label": "Weighted average exercise price of other equity instruments exercisable in share-based payment arrangement" } }, "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r337" ] }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019", "presentation": [ "http://okyopharma.com/role/ScheduleOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, exercised" } }, "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r337" ] }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019", "presentation": [ "http://okyopharma.com/role/ScheduleOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, granted" } }, "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) granted in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r337" ] }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019", "presentation": [ "http://okyopharma.com/role/ScheduleOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted average exercise price, outstanding beginning balance", "periodEndLabel": "Weighted average exercise price, outstanding ending balance", "label": "Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement" } }, "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r337" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019", "presentation": [ "http://okyopharma.com/role/ScheduleOfOptionsOutstandingAndWeightedAverageExercisePriceDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Ending balance, Weighted Average Exercise price, Exercisable", "label": "Weighted average exercise price of share options exercisable in share-based payment arrangement" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r70", "r133" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019", "presentation": [ "http://okyopharma.com/role/ScheduleOfOptionsOutstandingAndWeightedAverageExercisePriceDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise price, Exercised" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r68", "r131" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019", "presentation": [ "http://okyopharma.com/role/ScheduleOfOptionsOutstandingAndWeightedAverageExercisePriceDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise price, Forfeited" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r67", "r130" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019", "presentation": [ "http://okyopharma.com/role/ScheduleOfOptionsOutstandingAndWeightedAverageExercisePriceDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise price, Granted" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r66", "r129" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019", "presentation": [ "http://okyopharma.com/role/ScheduleOfOptionsOutstandingAndWeightedAverageExercisePriceDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance, Weighted Average Exercise price, outstanding", "periodEndLabel": "Ending balance, Weighted Average Exercise price, outstanding", "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r65", "r69", "r128", "r132" ] }, "OKYO_WeightedAverageNumberOfOrdinarySharesInIssue": { "xbrltype": "sharesItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "WeightedAverageNumberOfOrdinarySharesInIssue", "presentation": [ "http://okyopharma.com/role/SummaryOfIncomeAndShareDataUsedInBasicAndDilutedLossPerShareComputationsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average number of ordinary shares in issue", "documentation": "Weighted average number of ordinary shares in issue." } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": { "xbrltype": "durationItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019", "presentation": [ "http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Weighted average contractual life of options outstanding" } }, "en": { "role": { "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r71" ] }, "OKYO_WillySimonMember": { "xbrltype": "domainItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "WillySimonMember", "presentation": [ "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Willy Simon [member]", "documentation": "Willy Simon [member]" } } }, "auth_ref": [] }, "OKYO_WriteOffDisposals": { "xbrltype": "monetaryItemType", "nsuri": "http://okyopharma.com/20260331", "localname": "WriteOffDisposals", "crdr": "credit", "presentation": [ "http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Write Off Disposals", "documentation": "Write off disposals.", "label": "WriteOffDisposals" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "WrittenCommunications", "presentation": [ "http://okyopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r328" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "10", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI", "URIDate": "2025-03-27" }, "r1": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_79&doctype=Standard", "URIDate": "2025-03-27" }, "r2": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2025-03-27" }, "r3": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r4": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI", "URIDate": "2025-03-27" }, "r5": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_c&doctype=Standard", "URIDate": "2025-03-27" }, "r6": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e_i&doctype=Standard", "URIDate": "2025-03-27" }, "r7": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r8": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e_viii&doctype=Standard", "URIDate": "2025-03-27" }, "r9": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2025-03-27" }, "r10": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73&doctype=Standard", "URIDate": "2025-03-27" }, "r11": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI", "URIDate": "2025-03-27" }, "r12": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "138", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_138&doctype=Standard", "URIDate": "2025-03-27" }, "r13": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_53&doctype=Standard", "URIDate": "2025-03-27" }, "r14": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Section": "Scope", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS19_g2-7_TI", "URIDate": "2025-03-27" }, "r15": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17&doctype=Standard", "URIDate": "2025-03-27" }, "r16": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "18", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2025-03-27" }, "r17": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "19", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_19&doctype=Standard", "URIDate": "2025-03-27" }, "r18": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard", "URIDate": "2025-03-27" }, "r19": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Section": "Disclosures", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI", "URIDate": "2025-03-27" }, "r20": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2025-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2025-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2025-03-27" }, "r21": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r22": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_67&doctype=Standard", "URIDate": "2025-03-27" }, "r23": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_a&doctype=Standard", "URIDate": "2025-03-27" }, "r24": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI", "URIDate": "2025-03-27" }, "r25": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "34", "IssueDate": "2025-01-01", "Paragraph": "16A", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=34&code=ifrs-tx-2025-en-r&anchor=para_16A_f&doctype=Standard", "URIDate": "2025-03-27" }, "r26": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118&doctype=Standard", "URIDate": "2025-03-27" }, "r27": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_126&doctype=Standard", "URIDate": "2025-03-27" }, "r28": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_10&doctype=Standard", "URIDate": "2025-03-27" }, "r29": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard", "URIDate": "2025-03-27" }, "r30": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_25&doctype=Standard", "URIDate": "2025-03-27" }, "r31": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_28&doctype=Standard", "URIDate": "2025-03-27" }, "r32": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35&doctype=Standard", "URIDate": "2025-03-27" }, "r33": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "44H", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44H_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r34": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r35": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "50", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2025-03-27" }, "r36": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2025-03-27" }, "r37": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2025-03-27" }, "r38": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_31_b&doctype=Standard", "URIDate": "2025-03-27" }, "r39": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r40": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r41": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r42": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r43": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r44": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ix", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r45": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r46": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_d&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r47": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_e&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r48": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r49": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2025-03-27" }, "r50": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2025-03-27" }, "r51": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2025-03-27" }, "r52": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "14", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2025-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2025-03-27" }, "r53": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "114", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_114&doctype=Standard", "URIDate": "2025-03-27" }, "r54": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "120", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_120_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r55": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "58", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_58&doctype=Standard", "URIDate": "2025-03-27" }, "r56": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "94", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_94&doctype=Standard", "URIDate": "2025-03-27" }, "r57": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "97", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_97&doctype=Standard", "URIDate": "2025-03-27" }, "r58": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS16_g51-60_TI", "URIDate": "2025-03-27" }, "r59": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Section": "Presentation", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS16_g47-50_TI", "URIDate": "2025-03-27" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "109", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_109&doctype=Standard", "URIDate": "2025-03-27" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "109A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_109A&doctype=Standard", "URIDate": "2025-03-27" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "120", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_120&doctype=Standard", "URIDate": "2025-03-27" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "132", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_132_b&doctype=Standard", "URIDate": "2025-03-27" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "44", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_44&doctype=Standard", "URIDate": "2025-03-27" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_vii&doctype=Standard", "URIDate": "2025-03-27" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2025-03-27" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2025-03-27" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "23B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_23B_a&doctype=Standard", "URIDate": "2025-03-27" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_25&doctype=Standard", "URIDate": "2025-03-27" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "42E", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_42E_e&doctype=Standard", "URIDate": "2025-03-27" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B52", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B52&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Section": "Scope", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI", "URIDate": "2025-03-27" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_c&doctype=Standard", "URIDate": "2025-03-27" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_e&doctype=Standard", "URIDate": "2025-03-27" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2025-03-27" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard", "URIDate": "2025-03-27" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2025-03-27" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2025-03-27" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_d&doctype=Standard", "URIDate": "2025-03-27" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_e&doctype=Standard", "URIDate": "2025-03-27" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_32&doctype=Standard", "URIDate": "2025-03-27" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_33&doctype=Standard", "URIDate": "2025-03-27" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS08_g20-24_TI", "URIDate": "2025-03-27" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2026-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "30A", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_30A_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103&doctype=Standard", "URIDate": "2025-03-27" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "108", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_108_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "119", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_119&doctype=Standard", "URIDate": "2025-03-27" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "122", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "122", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a&doctype=Standard", "URIDate": "2025-03-27" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "124", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124_a&doctype=Standard", "URIDate": "2025-03-27" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "124", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124&doctype=Standard", "URIDate": "2025-03-27" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "133", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_133_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a&doctype=Standard", "URIDate": "2025-03-27" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_b&doctype=Standard", "URIDate": "2025-03-27" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160&doctype=Standard", "URIDate": "2025-03-27" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "168", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_168_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "169", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_169&doctype=Standard", "URIDate": "2025-03-27" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "192", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_192&doctype=Standard", "URIDate": "2025-03-27" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_i&doctype=Standard", "URIDate": "2025-03-27" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_c&doctype=Standard", "URIDate": "2025-03-27" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e_i&doctype=Standard", "URIDate": "2025-03-27" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "e", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e&doctype=Standard", "URIDate": "2025-03-27" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200&doctype=Standard", "URIDate": "2025-03-27" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "203", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_203&doctype=Standard", "URIDate": "2025-03-27" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "204", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_204&doctype=Standard", "URIDate": "2025-03-27" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "227", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_227&doctype=Standard", "URIDate": "2025-03-27" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "230", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_230_b&doctype=Standard", "URIDate": "2025-03-27" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "231", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_231&doctype=Standard", "URIDate": "2025-03-27" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2025-03-27" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2025-03-27" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "246", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_246_f&doctype=Standard", "URIDate": "2025-03-27" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263&doctype=Standard", "URIDate": "2025-03-27" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "266", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_266&doctype=Standard", "URIDate": "2025-03-27" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_vii&doctype=Standard", "URIDate": "2025-03-27" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard", "URIDate": "2025-03-27" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "64A", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_64A_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_a&doctype=Standard", "URIDate": "2025-03-27" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_b&doctype=Standard", "URIDate": "2025-03-27" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_iii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_iv&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_104&doctype=Standard", "URIDate": "2025-03-27" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_a&doctype=Standard", "URIDate": "2025-03-27" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_i&doctype=Standard", "URIDate": "2025-03-27" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106&doctype=Standard", "URIDate": "2025-03-27" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_a&doctype=Standard", "URIDate": "2025-03-27" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_h&doctype=Standard", "URIDate": "2025-03-27" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_i&doctype=Standard", "URIDate": "2025-03-27" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "k", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_k&doctype=Standard", "URIDate": "2025-03-27" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard", "URIDate": "2025-03-27" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "61", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_61_a&doctype=Standard", "URIDate": "2025-03-27" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "61", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_61&doctype=Standard", "URIDate": "2025-03-27" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "69", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_69&doctype=Standard", "URIDate": "2025-03-27" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_7&doctype=Standard", "URIDate": "2025-03-27" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard", "URIDate": "2025-03-27" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a&doctype=Standard", "URIDate": "2025-03-27" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79&doctype=Standard", "URIDate": "2025-03-27" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_a&doctype=Standard", "URIDate": "2025-03-27" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_c&doctype=Standard", "URIDate": "2025-03-27" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_b&doctype=Standard", "URIDate": "2025-03-27" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_d&doctype=Standard", "URIDate": "2025-03-27" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "91", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_91_a&doctype=Standard", "URIDate": "2025-03-27" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "91", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_91_b&doctype=Standard", "URIDate": "2025-03-27" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "99", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_99&doctype=Standard", "URIDate": "2025-03-27" }, "r171": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "80", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_80_a&doctype=Standard", "URIDate": "2025-03-27" }, "r172": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "80", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_80_b&doctype=Standard", "URIDate": "2025-03-27" }, "r173": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "80", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_80_c&doctype=Standard", "URIDate": "2025-03-27" }, "r174": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "80", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_80_e&doctype=Standard", "URIDate": "2025-03-27" }, "r175": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "138", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_138_a&doctype=Standard", "URIDate": "2025-03-27" }, "r176": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "147", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_147_c&doctype=Standard", "URIDate": "2025-03-27" }, "r177": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "21", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_21_c&doctype=Standard", "URIDate": "2025-03-27" }, "r178": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "21", "Subparagraph": "j", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_21_j&doctype=Standard", "URIDate": "2025-03-27" }, "r179": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "16", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16_a&doctype=Standard", "URIDate": "2025-03-27" }, "r180": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "16", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16_b&doctype=Standard", "URIDate": "2025-03-27" }, "r181": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Section": "A Statement of cash flows for an entity other than a financial institution", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI", "URIDate": "2025-03-27" }, "r182": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r183": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "B6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r184": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "IE63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2025-03-27" }, "r185": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "B89", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_B89_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r186": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "B89", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r187": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "B89", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_B89_d&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r188": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2025-03-27" }, "r189": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "96", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_96_a&doctype=Standard", "URIDate": "2025-03-27" }, "r190": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "96", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_96_b&doctype=Standard", "URIDate": "2025-03-27" }, "r191": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35H", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2025-03-27" }, "r192": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B11", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B11&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r193": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B11D", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B11D_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r194": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r195": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "IG20B", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_IG20B&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r196": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "IG31A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r197": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard", "URIDate": "2025-03-27" }, "r198": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2025-03-27" }, "r199": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "103", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103_a&doctype=Standard", "URIDate": "2025-03-27" }, "r200": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "103", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103_b&doctype=Standard", "URIDate": "2025-03-27" }, "r201": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "103", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103_d&doctype=Standard", "URIDate": "2025-03-27" }, "r202": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "193", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_193_a&doctype=Standard", "URIDate": "2025-03-27" }, "r203": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "193", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_193_b&doctype=Standard", "URIDate": "2025-03-27" }, "r204": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "193", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_193_c&doctype=Standard", "URIDate": "2025-03-27" }, "r205": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "193", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_193_e&doctype=Standard", "URIDate": "2025-03-27" }, "r206": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "234", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_234_c&doctype=Standard", "URIDate": "2025-03-27" }, "r207": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "234", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_234_i&doctype=Standard", "URIDate": "2025-03-27" }, "r208": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r209": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r210": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r211": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "102", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_102&doctype=Standard", "URIDate": "2025-03-27" }, "r212": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_103&doctype=Standard", "URIDate": "2025-03-27" }, "r213": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_108&doctype=Standard", "URIDate": "2025-03-27" }, "r214": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_70&doctype=Standard", "URIDate": "2025-03-27" }, "r215": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard", "URIDate": "2025-03-27" }, "r216": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r217": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "IG6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r218": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r219": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r220": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r221": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r222": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r224": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r225": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r226": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r227": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r228": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r229": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r230": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r231": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r232": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r233": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K" }, "r234": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1" }, "r235": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r236": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r237": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r238": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "2" }, "r239": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "1" }, "r240": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2" }, "r241": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r242": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r243": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r244": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r245": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r246": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r247": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r248": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r249": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r250": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r251": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r252": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r253": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r254": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r255": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r256": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r257": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r258": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r259": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r260": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r261": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r262": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r263": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 6-K", "Section": "General Instruction", "Subsection": "B" }, "r264": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 8-K", "Section": "1.05" }, "r265": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 8-K", "Section": "1.05", "Subsection": "Instruction", "Paragraph": "2" }, "r266": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 8-K", "Section": "1.05", "Subsection": "a" }, "r267": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r268": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r269": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r270": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r271": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r272": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r273": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r274": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r275": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r276": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r277": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r279": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r280": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r281": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r282": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r283": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r284": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r285": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r286": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r287": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r288": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r289": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r290": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r291": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r292": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r293": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r294": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r295": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r296": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r297": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r298": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r299": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r300": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r301": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r302": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r303": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r304": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r305": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r306": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r307": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r308": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r309": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r310": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r311": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r312": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r313": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r314": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r315": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r316": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106" }, "r317": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1" }, "r318": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r319": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r320": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r321": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "2" }, "r322": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "1" }, "r323": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2" }, "r324": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r325": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r326": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-X", "Number": "210", "Section": "2", "Subsection": "2" }, "r327": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r328": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r329": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r330": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "80", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_80&doctype=Standard", "URIDate": "2025-03-27" }, "r331": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_37&doctype=Standard", "URIDate": "2025-03-27" }, "r332": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "9", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_9&doctype=Standard", "URIDate": "2025-03-27" }, "r333": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16&doctype=Standard", "URIDate": "2025-03-27" }, "r334": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2025-03-27" }, "r335": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard", "URIDate": "2025-03-27" }, "r336": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r337": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r338": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_7&doctype=Standard", "URIDate": "2025-03-27" }, "r339": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "10", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_10_e&doctype=Standard", "URIDate": "2025-03-27" }, "r340": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_108&doctype=Standard", "URIDate": "2025-03-27" }, "r341": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "112", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_112_c&doctype=Standard", "URIDate": "2025-03-27" }, "r342": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_117&doctype=Standard", "URIDate": "2025-03-27" }, "r343": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard", "URIDate": "2025-03-27" }, "r344": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard", "URIDate": "2025-03-27" }, "r345": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r346": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78&doctype=Standard", "URIDate": "2025-03-27" }, "r347": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "85", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_85&doctype=Standard", "URIDate": "2025-03-27" } } }